fluorouracil has been researched along with Body Weight in 234 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " polysaccharides (PCCL) on 5-fluorouracil-(5-FU)-induced intestinal mucositis (IM) in mice." | 8.12 | Protective effect of polysaccharides isolated from the seeds of Cuscuta chinensis Lam. on 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Z; Ji, Y; Lu, H; Luo, R; Tan, W; Tian, C; You, Y; Zhao, X; Zhou, L; Zhou, W; Zhou, X, 2022) |
| " We evaluated the effect of WMP on CIM by observing the general conditions of the mice (body weight, food intake, spleen weight, diarrhea score, and hematoxylin and eosin stained tissues)." | 8.12 | Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation. ( Chen, BY; Liu, F; Liu, HX; Lu, DX; Lu, Y; Sun, ZG; Wu, H; Yan, J, 2022) |
| "Intestinal mucositis is a commonly encountered toxic side effect in patients undergoing 5-fluorouracil (5-FU)-based chemotherapy." | 8.02 | Amelioration of 5-fluorouracil-induced intestinal mucositis by Streptococcus thermophilus ST4 in a mouse model. ( Chen, WJ; Chu, HF; Shen, SR; Shen, TL; Wang, YR; Wu, SH, 2021) |
| "In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model." | 7.91 | Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019) |
| "The aim of the present study was to determine the efficacy of trabectedin combined with FOLFIRI (irinotecan, leucovorin and 5-fluorouracil) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (iPDOX) mouse model." | 7.91 | Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Clary, B; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019) |
| " The aim of this study was to test whether oral administration of a synbiotic (Simbioflora®) preparation containing Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus and Bifidobacterium lactis plus fructooligosaccharide could help control mucosal inflammation in experimental mucositis induced by 5-fluorouracil (5-FU)." | 7.88 | Oral administration of Simbioflora® (synbiotic) attenuates intestinal damage in a mouse model of 5-fluorouracil-induced mucositis. ( Almeida-Leite, CM; Cardoso, VN; Costa, GMF; Faria, AMC; Generoso, SV; Maioli, TU; Martins, FS; Martins, VD; Rodrigues, NM; Souza, ELS; Trindade, LM, 2018) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 7.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "Disturbed homeostasis of gut microbiota has been suggested to be closely associated with 5-fluorouracil (5-Fu) induced mucositis." | 7.85 | Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis. ( Huang, F; Li, HL; Lu, L; Qin, LY; Qiu, SP; Shi, HL; Wang, P; Wang, XS; Wu, H; Wu, XJ; Zhang, BB, 2017) |
| "Although the mechanisms of 5-fluorouracil (5-FU)-induced diarrhea remain unclear, accumulating evidence has indicated that changes in the mucosal immune system and aquaporins (AQPs) may play a role in its pathogenesis." | 7.79 | 5-Fluorouracil induces diarrhea with changes in the expression of inflammatory cytokines and aquaporins in mouse intestines. ( Hasegawa, S; Horie, S; Matsumoto, K; Nakagawa, T; Narita, M; Nishizaki, M; Sagara, A; Sakai, H; Sato, K; Shoji, T; Tokuyama, S, 2013) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 7.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| "Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break." | 7.69 | Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. ( Cronin, B; Cunningham, D; Findlay, M; Flower, M; Hickish, T; Husband, J; Iveson, A; Ott, R; Pratt, B; Young, H, 1996) |
| "One hundred twenty-four patients with metastatic breast cancer were treated with 40 mg of megestrol acetate four times daily." | 7.67 | Megestrol acetate therapy for advanced breast cancer. ( Cohen, SC; Gregory, EJ; Mims, CH; Oines, DW, 1985) |
| "The binding of 5-fluorouracil to polybutylcyanoacrylate nanoparticles yielded an enhanced efficacy against Crocker sarcoma S 180 and a higher toxicity of the drug measured by induced leukopenia, body weight loss and premature death." | 7.66 | Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. ( Hartmann, HR; Kreuter, J, 1983) |
| "5-Fluorouracil (5-FU) is a chemotherapy agent that is widely used in clinical oncologic practice." | 5.62 | Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice. ( Chang, CW; Chen, YJ; Hsieh, CH; Liu, CY; Liu, JH; Tsai, TH, 2021) |
| "Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is usually based on two- or three-drug chemotherapy regimens with fluoropyrimidine (5-fluorouracil (5-FU) or capecitabine), oxaliplatin and/or irinotecan, combined with either anti-VEGF (bevacizumab) or, for RAS wild-type (WT) tumors, anti-EGFR antibodies (panitumumab or cetuximab)." | 5.51 | Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line tre ( Dechow, T; Ettrich, TJ; Fruehauf, S; Fuchs, M; Heinemann, V; Hoyer, I; Kaiser, F; Karthaus, M; Kiani, A; König, A; Kurreck, A; Modest, DP; Müller, L; Quante, M; Reinacher-Schick, A; Roderburg, C; Schwaner, I; Sommerhäuser, G; Stahler, A; Stintzing, S; von Weikersthal, LF, 2022) |
| "Mucositis was induced by intraperitoneal injection of 300 mg/kg 5-FU." | 5.48 | Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model. ( Alvarez Leite, JI; Antunes Fernandes, SO; Cardoso, VN; Cassali, GD; da Gama, MAS; de Barros, PAV; de Sales E Souza, ÉL; de Vasconcelos Generoso, S; Dos Reis, DC; Dos Santos Martins, F; Lacerda Leocádio, PC; Mendes Miranda, SE; Rabelo Andrade, ME, 2018) |
| "Mouse body weight was monitored daily." | 5.42 | Alanyl-glutamine attenuates 5-fluorouracil-induced intestinal mucositis in apolipoprotein E-deficient mice. ( Alves, LA; Aquino, CC; Araújo, CV; Bertolini, LR; Brito, GA; Costa, TB; Figueiredo, IL; Lazzarotto, CR; Lima, AA; Oriá, RB; Ribeiro, RA, 2015) |
| "Intestinal mucositis is a common toxic side effect in cancer patients receiving high-dose chemotherapy." | 5.42 | Bifidobacterium infantis has a beneficial effect on 5-fluorouracil-induced intestinal mucositis in rats. ( Chong, P; Feng, WD; Shi, HP; Xue, CL; Yang, T; Yu, HL; Yu, M; Yuan, KT, 2015) |
| "5-Fluorouracil (5-FU) is a cytostatic anti-tumor drug which is known to have immunosuppressive activities." | 5.31 | Effects on fetal thymocyte populations and postnatal T-cell-dependent immune functions after maternal exposure to 5-fluorouracil during pregnancy in mice. ( Horii, I; Inoue, T, 2002) |
| "Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1." | 5.09 | Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). ( Barni, S; Battelli, N; Casaretti, R; Cascinu, S; Catalano, G; Cellerino, R; Comella, G; Frontini, L; Labianca, R; Pirovano, M; Zonato, S, 1999) |
| "Cancer and Leukemia Group B (CALGB) study 8541, a randomized study of schedule and dose of adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) for stage II breast cancer patients with positive regional lymph nodes, provided data on 1,435 women for analysis." | 5.08 | Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. ( Budman, DR; Hargis, JB; Henderson, IC; Hollis, DR; Rosner, GL; Schilsky, RL; Weiss, RB, 1996) |
| "30 patients with advanced metastatic gastric adenocarcinoma, having a measurable indicator lesion, were randomized (1:2) to receive (intravenously) either weekly 5-fluorouracil alone (15 mg/kg) or combination treatment with cyclophosphamide (20 mg/kg) given on day 1 and 5-FU (15 mg/kg) given weekly on weeks 2-5, beginning on day 8." | 5.05 | Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma. ( Bateman, JR; Chlebowski, RT; Glass, A; Silverberg, I; Weiner, JM, 1985) |
| " polysaccharides (PCCL) on 5-fluorouracil-(5-FU)-induced intestinal mucositis (IM) in mice." | 4.12 | Protective effect of polysaccharides isolated from the seeds of Cuscuta chinensis Lam. on 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Z; Ji, Y; Lu, H; Luo, R; Tan, W; Tian, C; You, Y; Zhao, X; Zhou, L; Zhou, W; Zhou, X, 2022) |
| " We evaluated the effect of WMP on CIM by observing the general conditions of the mice (body weight, food intake, spleen weight, diarrhea score, and hematoxylin and eosin stained tissues)." | 4.12 | Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation. ( Chen, BY; Liu, F; Liu, HX; Lu, DX; Lu, Y; Sun, ZG; Wu, H; Yan, J, 2022) |
| "Intestinal mucositis is a commonly encountered toxic side effect in patients undergoing 5-fluorouracil (5-FU)-based chemotherapy." | 4.02 | Amelioration of 5-fluorouracil-induced intestinal mucositis by Streptococcus thermophilus ST4 in a mouse model. ( Chen, WJ; Chu, HF; Shen, SR; Shen, TL; Wang, YR; Wu, SH, 2021) |
| "The aim of the present study was to determine the efficacy of trabectedin combined with FOLFIRI (irinotecan, leucovorin and 5-fluorouracil) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (iPDOX) mouse model." | 3.91 | Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Clary, B; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019) |
| "5-Fluorouracil (5-FU)-based chemotherapy often causes several drawbacks including weight loss, diarrhea, myelosuppression, and the intestinal mucositis." | 3.91 | Qingjie Fuzheng Granule attenuates 5-fluorouracil-induced intestinal mucosal damage. ( Chen, W; Jin, Y; Lin, J; Lisha, L; Peng, J; Zhang, L, 2019) |
| "In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model." | 3.91 | Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019) |
| " The aim of this study was to test whether oral administration of a synbiotic (Simbioflora®) preparation containing Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus and Bifidobacterium lactis plus fructooligosaccharide could help control mucosal inflammation in experimental mucositis induced by 5-fluorouracil (5-FU)." | 3.88 | Oral administration of Simbioflora® (synbiotic) attenuates intestinal damage in a mouse model of 5-fluorouracil-induced mucositis. ( Almeida-Leite, CM; Cardoso, VN; Costa, GMF; Faria, AMC; Generoso, SV; Maioli, TU; Martins, FS; Martins, VD; Rodrigues, NM; Souza, ELS; Trindade, LM, 2018) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 3.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "Disturbed homeostasis of gut microbiota has been suggested to be closely associated with 5-fluorouracil (5-Fu) induced mucositis." | 3.85 | Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis. ( Huang, F; Li, HL; Lu, L; Qin, LY; Qiu, SP; Shi, HL; Wang, P; Wang, XS; Wu, H; Wu, XJ; Zhang, BB, 2017) |
| "Although the mechanisms of 5-fluorouracil (5-FU)-induced diarrhea remain unclear, accumulating evidence has indicated that changes in the mucosal immune system and aquaporins (AQPs) may play a role in its pathogenesis." | 3.79 | 5-Fluorouracil induces diarrhea with changes in the expression of inflammatory cytokines and aquaporins in mouse intestines. ( Hasegawa, S; Horie, S; Matsumoto, K; Nakagawa, T; Narita, M; Nishizaki, M; Sagara, A; Sakai, H; Sato, K; Shoji, T; Tokuyama, S, 2013) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 3.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| " injection with 5-fluorouracil/leukovorin (5-FU/LV) for 5 days (20 mg and 10 mg/kg body weight respectively)." | 3.73 | Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. ( El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V, 2005) |
| "To verify whether fluorouracil (FU) clearance (CL) and volume of distribution (V(ss)) are better correlated with specific body compartments, such as body cell mass (BCM), total body water (TBW) or fat free mass (FFM), rather than with body surface area (BSA) or total body weight (BW)." | 3.71 | Relationships between body composition parameters and fluorouracil pharmacokinetics. ( Ferrari, M; Ferrazzi, E; Gusella, M; Padrini, R; Toso, S, 2002) |
| " To throw light on these questions, we investigated the effects of HBO and 5-fluorouracil (5-FU), individually and in combination, on Sarcoma 180 implants in mice." | 3.71 | Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs. ( Furuyama, N; Kouda, K; Nakajima, N; Nunomura, M; Oda, K; Saito, N; Takiguchi, N, 2001) |
| "Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break." | 3.69 | Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. ( Cronin, B; Cunningham, D; Findlay, M; Flower, M; Hickish, T; Husband, J; Iveson, A; Ott, R; Pratt, B; Young, H, 1996) |
| "The present studies examined the anti-proliferative effects of diallyl disulfide (DADS) on the growth of human colon tumor cell line, HCT-15, xenografts in 6-wk-old female NCr nu/nu mice with an initial body weight of 20-22 g." | 3.69 | Diallyl disulfide suppresses the growth of human colon tumor cell xenografts in athymic nude mice. ( Milner, JA; Sundaram, SG, 1996) |
| "In a comparative study on the effect of CMF (Combination of Cyclophosphamid, Methotroxate and 5-Fluorouracil) on the pre and postmenopausal women with breast cancer, a number of differences were observed in circulating plasma lipid concentration." | 3.68 | Studies on the changes in plasma lipids and lipoproteins in CMF treated breast cancer patients. ( Devi, CS; Marar, T; Subramaniam, S, 1991) |
| "The effects of 1-beta-D-arabinosylcytosine (ara-C) and 5-fluorouracil (5-FU) on body weight, and the contents of putrescine, spermidine and spermine in 14 different tissues were examined in rats given these drugs for 5 days." | 3.68 | Polyamine increase in rat tissues treated with 1-beta-D-arabinosylcytosine and 5-fluorouracil. ( Nagase, S; Saito, T; Sato, S; Watanabe, S, 1993) |
| "One hundred twenty-four patients with metastatic breast cancer were treated with 40 mg of megestrol acetate four times daily." | 3.67 | Megestrol acetate therapy for advanced breast cancer. ( Cohen, SC; Gregory, EJ; Mims, CH; Oines, DW, 1985) |
| "The binding of 5-fluorouracil to polybutylcyanoacrylate nanoparticles yielded an enhanced efficacy against Crocker sarcoma S 180 and a higher toxicity of the drug measured by induced leukopenia, body weight loss and premature death." | 3.66 | Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. ( Hartmann, HR; Kreuter, J, 1983) |
| " High doses of 5-fluorouracil (5-FU) and cyclophosphamide (CP) given parenterally for 6 days caused a partial decrease in whole body weight and the microsomal enzyme content such as cytochrome P-450 and cytochrome b5." | 3.65 | Antitumor agents. I. Effect of 5-fluorouracil and cyclophosphamide on liver microsomes and thymus of rat. ( Asai, N; Kato, Y; Noda, N; Ogiso, T, 1976) |
| "The effects of single agent therapy with 1-(-chloroethyl)-3-cyclohexyl-1-nitrosourea, 5-fluorouracil, and 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide on a human malignant melanoma transplanted and passed serially in thymusless nude mouse were studied." | 3.65 | Chemotherapy of a human malignant melanoma transplanted in the nude mouse. ( Jacobsen, GK; Povlsen, CO, 1975) |
| "Patients suffering from advanced colorectal cancer can experience unintended weight loss and/or treatment-induced gastrointestinal toxicity." | 2.75 | Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomize ( Essenbreis, M; Hasenberg, T; Herold, A; Post, S; Shang, E, 2010) |
| "Oral mucositis is a frequent and potentially severe complication of radiation or chemotherapy for cancer." | 2.71 | Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies. ( Aksungur, P; Iskit, AB; Senel, S; Squier, CA; Sungur, A; Unal, S, 2004) |
| "Obesity is a risk factor for the development of colon carcinoma." | 2.71 | Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. ( Benson, AB; Catalano, PJ; Fuchs, CS; Haller, DG; Macdonald, JS; Mayer, RJ; Meyerhardt, JA, 2003) |
| " Furthermore, the survival was elevated in proportion to the increase of total dosage of futraful." | 2.65 | [Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)]. ( Abe, O; Akiyama, H; Hattori, T; Hayasaka, A; Inokuchi, K; Inoue, K; Ito, I; Kasai, Y; Kikuchi, K; Kondo, T; Muto, T; Nakajima, T; Sugie, S; Taguchi, T, 1982) |
| "5-Fluorouracil (5-FU) was a key chemotherapeutic agent in the treatment of different solid tumors." | 1.72 | ROS and iron homeostasis dependent ferroptosis play a vital role in 5-Fluorouracil induced cardiotoxicity in vitro and in vivo. ( Li, D; Song, C; Zhang, J; Zhao, X, 2022) |
| "Changes in body weight and white blood cell count were measured to determine the optimal dosing schedule." | 1.62 | Therapeutic Effects of GGsTop ( Makino, K; Takeuchi, I; Tanaka, K, 2021) |
| "5-Fluorouracil (5-FU) is a chemotherapy agent that is widely used in clinical oncologic practice." | 1.62 | Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice. ( Chang, CW; Chen, YJ; Hsieh, CH; Liu, CY; Liu, JH; Tsai, TH, 2021) |
| "A model animal of oral mucositis was prepared by injecting an acetic acid aqueous solution into the buccal mucosa of rats to which a 5-FU solution had been previously administered." | 1.56 | A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments. ( Kawamata, R; Makino, K; Takeuchi, I, 2020) |
| "Malnutrition is a common clinical symptom in cancer patients after chemotherapy, which is characterized by muscle wasting and metabolic dysregulation." | 1.56 | The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats. ( Chen, H; Guo, Y; Liu, Y; Xu, C; Yao, Q; Zhang, F, 2020) |
| "Mucositis was induced by intraperitoneal injection of 5-FU (400 mg/kg)." | 1.51 | Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis. ( Choi, HS; Chun, HJ; Jeen, YT; Keum, B; Kim, CD; Kim, ES; Kim, SH; Lee, HS; Lee, JM; Seo, YS; Um, SH; Yoo, IK, 2019) |
| "Forty PDOX mouse models with colon cancer growing on the peritoneum were divided into 4 groups of 10 mice each by measuring the tumor size and fluorescence intensity: untreated control; 5-fluorouracil (5-FU) (50 mg/kg, once a week for two weeks, ip) and oxaliplatinum (OXA) (6 mg/kg, once a week for two weeks, ip); o-rMETase (100 units/day, oral 14 consecutive days); combination 5-FU + OXA and o-rMETase." | 1.51 | Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model. ( Bouvet, M; Clary, B; Han, Q; Higuchi, T; Hoffman, RM; Park, JH; Singh, SR; Sugisawa, N; Tan, Y; Yamamoto, J; Yoon, SN; Zhao, M, 2019) |
| "1." | 1.51 | Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam. ( Fujiike, M; Fukuno, S; Konishi, H; Nagai, K; Sasaki, Y, 2019) |
| "Fatigue is a common symptom in many diseases and disorders and can reduce quality of life, yet lacks an adequate pharmacological intervention." | 1.51 | Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays. ( Cullen, MJ; Dougherty, JP; Gershengorn, MC; Springer, DA, 2019) |
| "Cancer chemotherapy is frequently accompanied by adverse effects, such as diarrhoea and leukopenia, which lead to malnutrition and a decrease in the patients' quality of life." | 1.51 | Nutritional treatment with an immune-modulating enteral formula alleviates 5-fluorouracil-induced adverse effects in rats. ( Ashida, K; Nakamura, K; Sasayama, A; Tonouchi, H; Yamaji, T, 2019) |
| "Mucositis was induced by intraperitoneal injection of 300 mg/kg 5-FU." | 1.48 | Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model. ( Alvarez Leite, JI; Antunes Fernandes, SO; Cardoso, VN; Cassali, GD; da Gama, MAS; de Barros, PAV; de Sales E Souza, ÉL; de Vasconcelos Generoso, S; Dos Reis, DC; Dos Santos Martins, F; Lacerda Leocádio, PC; Mendes Miranda, SE; Rabelo Andrade, ME, 2018) |
| "Mucositis is the most common side effect due to chemotherapy or radiotherapy." | 1.46 | Effect of Conjugated Linoleic Acid-enriched Butter After 24 hours of Intestinal Mucositis Induction. ( Andrade, ME; Barros, PA; Cardoso, VN; da Gama, MA; de Sales E Souza, ÉL; Fernandes, SO; Generoso, SV; Lopes, FC; Martins, FD; Miranda, SE, 2017) |
| "Gastrointestinal toxicity is the most common adverse effect of chemotherapy." | 1.43 | Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats. ( Forsgård, RA; Frias, R; Holma, R; Korpela, R; Lindén, J; Österlund, P; Spillmann, T, 2016) |
| "Intestinal mucositis is a common toxic side effect in cancer patients receiving high-dose chemotherapy." | 1.42 | Bifidobacterium infantis has a beneficial effect on 5-fluorouracil-induced intestinal mucositis in rats. ( Chong, P; Feng, WD; Shi, HP; Xue, CL; Yang, T; Yu, HL; Yu, M; Yuan, KT, 2015) |
| "Mouse body weight was monitored daily." | 1.42 | Alanyl-glutamine attenuates 5-fluorouracil-induced intestinal mucositis in apolipoprotein E-deficient mice. ( Alves, LA; Aquino, CC; Araújo, CV; Bertolini, LR; Brito, GA; Costa, TB; Figueiredo, IL; Lazzarotto, CR; Lima, AA; Oriá, RB; Ribeiro, RA, 2015) |
| "Cucurbitacin B is a plant-derived tetracyclic triterpenoid, which has been used for a variety of cancers, especially human hepatoma." | 1.42 | Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells. ( Chen, D; Hu, H; Huang, Z; Qiao, M; Sun, Y; Zhang, J; Zhao, X; Zhou, J, 2015) |
| "5-Fluorouracil (5-FU) is a cytostatic drug associated with chemotherapy-induced cognitive impairments that many cancer patients experience after treatment." | 1.38 | Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. ( Bennett, G; ElBeltagy, M; Lyons, L; Wigmore, P, 2012) |
| " SERMS are a safe and effective intervention in dysphagic patients undergoing neoadjuvant chemotherapy for esophageal cancer." | 1.38 | Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer. ( Gilani, SQ; Jain, PK; Pellen, MG; Razack, A; Sabri, S, 2012) |
| "5-Fluorouracil (5-FU) is a small, very membrane permeable drug that is poorly retained within the aqueous compartment of liposomal nanoparticles (LNP)." | 1.37 | Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. ( Bally, MB; Edwards, K; Hare, JI; Kapanen, AI; Karlsson, G; Ramsay, E; Thomas, AM, 2011) |
| "Malondialdehyde levels were significantly higher in the 5-FU groups than in the 5-FU + AM groups." | 1.36 | Covering the colon anastomoses with amniotic membrane prevents the negative effects of early intraperitoneal 5-FU administration on anastomotic healing. ( Citgez, B; Ipcioglu, OM; Isgor, A; Kartal, A; Ozcan, O; Ozdilli, K; Polat, N; Torun, P; Uludag, M; Yetkin, G, 2010) |
| " Chemotherapy was administered via the penil vein, using the same dosing scheme and duration as the second group." | 1.35 | Effect of early preoperative 5-fluorouracil on the integrity of colonic anastomoses in rats. ( Berber, I; Kara, M; Koyuturk, M; Krand, O; Ozel, L; Ozel, MS; Ozkan, KS; Tellioglu, G; Toros, AB, 2009) |
| "Although patients with metastatic prostate cancer can benefit from androgen ablation, most of them will die of prostate cancer progression to an androgen-refractory state." | 1.34 | Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. ( Hung, H, 2007) |
| "In this study we propose for the first time a limited sampling strategy to estimate the individual pharmacokinetic parameters of both irinotecan and SN-38 in patients treated with the irinotecan plus 5-fluorouracil (FOLFIRI) regimen." | 1.34 | A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ( Abderrahim, AG; Bressolle, FM; Duffour, J; Pinguet, F; Poujol, S; Ychou, M, 2007) |
| "Oral mucositis was induced in hamsters through a combination treatment of 5-fluorouracil and mild abrasion of the cheek pouch." | 1.33 | Evaluation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters. ( Araki, H; Cui, R; Li, B; Mitsuhashi, H; Suemaru, K, 2006) |
| "The purpose of this investigation was to evaluate the effectiveness of oral 5-(phenylthio)acyclouridine (PTAU) in improving the pharmacokinetics and bioavailability of oral uridine." | 1.33 | 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ( Al Safarjalani, ON; El Kouni, MH; Naguib, FN; Rais, RH; Schinazi, RF; Shi, J; Zhou, XJ, 2005) |
| "Human colon cancer cells were injected subcutaneous in nude mice." | 1.33 | Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer. ( El-Salhy, M; Tjomsland, V, 2005) |
| "Treatment with uridine alone did not protect from FUra toxicity at the dose of 200 mg/kg as all mice died." | 1.33 | Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor. ( Al Safarjalani, ON; el Kouni, MH; Naguib, FN; Rais, R; Schinazi, RF; Shi, J, 2006) |
| "Body weight was measured once a week." | 1.32 | Protective effects of glutathione on 5-fluorouracil-induced myelosuppression in mice. ( Hara, T; Kakuni, M; Kimoto, N; Kojima, S; Mizutani, M; Sato, H; Suzuki, K; Takaba, K; Takeda, T, 2003) |
| "We prepared a colon cancer-bearing Yoshida sarcoma rat model to examine the dose-response relationship of antitumor activity of intracolonically or orally administered 5-fluorouracil (5-FU; 45, 30, 20, 13, and 8 mg/kg)." | 1.32 | A comparative pharmacology study between the intracolonic and oral routes of 5-FU administration in a colon cancer-bearing Yoshida sarcoma rat model. ( Fujimura, A; Goto, T; Kobayashi, E; Tomizawa, N, 2004) |
| " This study was designed to investigate the effects of angiogenesis inhibitor TNP-470 in combination with 5-fluorouracil (5-FU) on the growth of human colon cancer cell line, LOVO, in vitro and in vivo." | 1.31 | [Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer]. ( Fan, YF; Huang, ZH; Nie, J, 2002) |
| " combined with HT (43 degrees C for 1 h) and 5-FU (30 mg / kg / day i." | 1.31 | Enhanced efficacy of radioimmunotherapy combined with systemic chemotherapy and local hyperthermia in xenograft model. ( Aburano, T; Hiramatsu, T; Kinuya, S; Konishi, S; Michigishi, T; Shuke, N; Takayama, T; Tonami, N; Watanabe, N; Yokoyama, K, 2000) |
| "5-Fluorouracil (5-FU) is a cytostatic anti-tumor drug which is known to have immunosuppressive activities." | 1.31 | Effects on fetal thymocyte populations and postnatal T-cell-dependent immune functions after maternal exposure to 5-fluorouracil during pregnancy in mice. ( Horii, I; Inoue, T, 2002) |
| " Therefore toxic potentiation of 5-FU due to simultaneous 1-LV dosing is presumed to be concerned with an increased ternary complex (FdUMP-TS-5,10-methylenetetrahydrofolate) formation and a greater extent of TS inhibition." | 1.30 | Effects of levofolinate calcium on subacute intravenous toxicity of 5-fluorouracil in rats. ( Fujii, H; Ichimura, A; Murakami, Y; Murata, A; Takagi, H; Tauchi, K; Yamashita, N, 1998) |
| " After 3 weeks of the ligation in two different groups of animals for in vitro and pharmacokinetic experiments, significant increases in serum bilirubin level and spleen weight were found in both groups." | 1.30 | Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats. ( Kobayashi, S; Kumai, T; Nakura, H; Nishiyama, T; Ogura, K; Sakata, SF; Tamaki, N; Tanaka, M; Tateishi, T; Watabe, T; Watanabe, M, 1999) |
| "A new dosage formulation of 5-fluorouracil incorporated in microspheres (5-FU-MS) was developed for the treatment of peritoneal carcinomatosis." | 1.29 | New formulation of 5-fluorouracil in microspheres reduces toxicity in mice. ( Hagiwara, A; Ikada, Y; Imanishi, T; Muranishi, S; Ohgaki, M; Sakakura, C; Sawai, K; Tabata, Y; Takahashi, T; Tsujimoto, H; Yamamoto, A; Yamazaki, J, 1996) |
| "Decreased body weight was observed in mice treated with 5-FU and UFT but not in those treated with S-1." | 1.29 | [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU]. ( Kouchi, Y; Maeda, Y; Morinaga, H; Ohuchida, A, 1996) |
| "Body weight was diminished significantly in rats receiving chemotherapy." | 1.29 | Combined preoperative irradiation and direct postoperative 5-fluorouracil without negative effects on early anastomotic healing in the rat colon. ( Biert, J; de Man, B; Hendriks, T; Hoogenhout, J; Wobbes, T, 1996) |
| "5 mg/kg), or cisplatin (4 mg/kg, by one shot) to TNP (120-140 mg/kg) with a 6-7 fractionated dosing schedule reduced s." | 1.29 | Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. ( Kakinuma, H; Kato, T; Matsuda, Y; Sato, K, 1994) |
| " The results suggest that the toxic effects of chemotherapy are dosing time dependent." | 1.29 | Circadian variation of 5-fluorouracil and cis-platinum toxicity in mice. ( Hirabayashi, N; Shakil, A; Toge, T, 1993) |
| " The bioavailability of UK-21 given p." | 1.28 | Antitumor activity of two novel low immunosuppressive fluoropyrimidines UK-21 and UK-25. ( Kato, T; Kitaichi, K; Koda, A; Mori, H; Sakamoto, O, 1992) |
| " with 950 mg/kg of OTC 4 hours before dosing with 5-FU." | 1.28 | Effects of L-2-oxothiazolidine-4-carboxylate, a cysteine pro-drug, on teratogenicity of 5-fluorouracil in mice. ( Deguchi, T; Mataki, Y; Naya, M; Noguchi, M; Yasuda, M, 1990) |
| " These results demonstrate that the enhanced incorporation of 5-FU into tumour RNA in vivo after pretreatment with TdR is related not to local effects on the tumour cells but rather to an increased bioavailability of the drug." | 1.27 | Modulation of 5-fluorouracil metabolism by thymidine. In vivo and in vitro studies on RNA-directed effects in rat liver and hepatoma. ( Engelbrecht, C; Lewan, L; Ljungquist, I; Yngner, T, 1984) |
| "Tegafur was administered for 24 weeks at respective doses of 90 mg, 120 mg and 150 mg/kg/day." | 1.27 | [Maximum tolerated dose of tegafur in rats]. ( Aoki, N; Hamada, S; Hirayama, R; Matsumura, J; Mishima, Y; Miyanaga, T; Takagi, Y, 1984) |
| "In groups 1, 2 and 3, urinary bladder tumors developed in 13 of 18, 0 of 20, and 4 of 19, respectively." | 1.27 | Effect of 1-hexylcarbamoyl-5-fluorouracil on development of rat urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Hirao, Y; Iwata, H; Matsuki, H; Okajima, E; Ozono, S; Sasaki, K; Takahashi, S; Tsunemi, K, 1988) |
| " At the dose of 250 mg/kg, all mice treated with 5-Fu died of toxicity but the mice treated with DMS-Fu survived and showed no obvious toxic effect." | 1.27 | [Effect and toxicity of entrapped polysiloxane 5-Fu polycondensate]. ( Fu, NW; Guo, R; Quan, LP; Zhang, LS, 1987) |
| " Weekly administration of FUra at 85 mg/kg resulted in toxicity expressed in body weight loss and in depressed peripheral WBC levels; however, the magnitude of these toxic effects decreased significantly by the 5th week of treatment." | 1.27 | Decreased host toxicity in vivo during chronic treatment with 5-flourouracil. ( Darnowski, JW; Lau-Cam, CA; Martin, DS; Sawyer, RC; Stolfi, RL, 1985) |
| " Consequently, they are either excluded from antitumor therapy or receive only reduced dosage regimens." | 1.26 | [Parenteral feeding during aggressive chemotherapy of various neoplasms]. ( Jehn, U; Kohlschütter, B, 1978) |
| "Urinary bladder tumors were induced in 18 of 20 rats (90." | 1.26 | [Effect of FT-207 on bladder cancer in rats induced by BBN. II: The effect of oral administration of FT-207 during oncogenesis of bladder cancer]. ( Babaya, K; Hiramatsu, T; Hirao, Y; Ijuin, M; Kihoin, K; Maruyama, Y; Ohara, S; Okajima, E; Tanaka, M, 1982) |
| " The most severe toxic effect of 5-FU, with 100% mortality, was observed when the drug was administered at 4 am, whereas at 12 am 5-FU was least toxic." | 1.26 | Circadian rhythm and 5-fluorouracil toxicity in C3H mice. ( Baughman, J; Popovic, P; Popovic, V, 1982) |
| " The mean lethal dose values of heated and unheated pertussis vaccines were similar in the actinomycin D enhancement assay, but the unheated vaccine was significantly more toxic in the mouse weight gain test." | 1.25 | Determination of endotoxicity in bacterial vaccines. ( Chan, YK; Feeley, JC; Miller, CE; Wong, KH, 1973) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 78 (33.33) | 18.7374 |
| 1990's | 52 (22.22) | 18.2507 |
| 2000's | 52 (22.22) | 29.6817 |
| 2010's | 41 (17.52) | 24.3611 |
| 2020's | 11 (4.70) | 2.80 |
| Authors | Studies |
|---|---|
| El-Far, M | 1 |
| Elmegeed, GA | 1 |
| Eskander, EF | 1 |
| Rady, HM | 1 |
| Tantawy, MA | 1 |
| Wu, Y | 2 |
| Hu, M | 1 |
| Yang, L | 2 |
| Li, X | 1 |
| Bian, J | 1 |
| Jiang, F | 1 |
| Sun, H | 1 |
| You, Q | 1 |
| Zhang, X | 1 |
| Takeuchi, I | 2 |
| Tanaka, K | 1 |
| Makino, K | 2 |
| Li, D | 1 |
| Song, C | 1 |
| Zhang, J | 4 |
| Zhao, X | 3 |
| Ji, Y | 1 |
| Zhou, W | 1 |
| Tan, W | 1 |
| Chen, Z | 1 |
| Lu, H | 3 |
| You, Y | 1 |
| Tian, C | 1 |
| Zhou, X | 1 |
| Zhou, L | 1 |
| Luo, R | 1 |
| Sommerhäuser, G | 1 |
| Kurreck, A | 1 |
| Stintzing, S | 1 |
| Heinemann, V | 1 |
| von Weikersthal, LF | 1 |
| Dechow, T | 1 |
| Kaiser, F | 1 |
| Karthaus, M | 1 |
| Schwaner, I | 1 |
| Fuchs, M | 1 |
| König, A | 1 |
| Roderburg, C | 1 |
| Hoyer, I | 1 |
| Quante, M | 1 |
| Kiani, A | 1 |
| Fruehauf, S | 1 |
| Müller, L | 1 |
| Reinacher-Schick, A | 1 |
| Ettrich, TJ | 1 |
| Stahler, A | 1 |
| Modest, DP | 1 |
| Dahlgren, D | 1 |
| Rosenqvist, E | 1 |
| Hellström, PM | 1 |
| Nygren, P | 1 |
| Kullenberg, F | 1 |
| Peters, K | 1 |
| Sjöblom, M | 1 |
| Lennernäs, H | 1 |
| Lu, DX | 1 |
| Liu, F | 1 |
| Wu, H | 2 |
| Liu, HX | 1 |
| Chen, BY | 1 |
| Yan, J | 1 |
| Lu, Y | 1 |
| Sun, ZG | 1 |
| Lee, JM | 2 |
| Yoo, IK | 1 |
| Kim, SH | 1 |
| Choi, HS | 1 |
| Kim, ES | 1 |
| Keum, B | 1 |
| Seo, YS | 1 |
| Jeen, YT | 1 |
| Chun, HJ | 1 |
| Lee, HS | 1 |
| Um, SH | 1 |
| Kim, CD | 1 |
| Zhu, G | 2 |
| Zhao, M | 3 |
| Han, Q | 3 |
| Tan, Y | 3 |
| Sun, YU | 2 |
| Bouvet, M | 3 |
| Singh, SR | 4 |
| Ye, J | 2 |
| Hoffman, RM | 4 |
| Park, JH | 1 |
| Higuchi, T | 2 |
| Yoon, SN | 1 |
| Sugisawa, N | 1 |
| Yamamoto, J | 1 |
| Clary, B | 2 |
| Nakamura, K | 1 |
| Tonouchi, H | 1 |
| Sasayama, A | 1 |
| Yamaji, T | 1 |
| Ashida, K | 1 |
| Kawamata, R | 1 |
| Chen, H | 1 |
| Xu, C | 1 |
| Zhang, F | 1 |
| Liu, Y | 1 |
| Guo, Y | 1 |
| Yao, Q | 1 |
| Zhang, Z | 1 |
| Hu, K | 1 |
| Miyake, K | 1 |
| Kiyuna, T | 1 |
| Oshiro, H | 1 |
| Wangsiricharoen, S | 1 |
| Kawaguchi, K | 1 |
| Razmjooei, S | 1 |
| Miyake, M | 1 |
| Chawla, SP | 1 |
| Liu, JH | 1 |
| Hsieh, CH | 1 |
| Liu, CY | 1 |
| Chang, CW | 1 |
| Chen, YJ | 1 |
| Tsai, TH | 1 |
| Shen, SR | 1 |
| Chen, WJ | 1 |
| Chu, HF | 1 |
| Wu, SH | 1 |
| Wang, YR | 1 |
| Shen, TL | 1 |
| Kato, S | 2 |
| Hamouda, N | 1 |
| Kano, Y | 1 |
| Oikawa, Y | 1 |
| Tanaka, Y | 2 |
| Matsumoto, K | 3 |
| Amagase, K | 2 |
| Shimakawa, M | 1 |
| Mao, G | 1 |
| Li, Q | 1 |
| Deng, C | 1 |
| Wang, Y | 3 |
| Ding, Y | 1 |
| Zhang, W | 1 |
| Chen, Y | 1 |
| Zhao, T | 1 |
| Wei, F | 1 |
| Wu, X | 2 |
| Shiomi, Y | 1 |
| Ohira, Y | 1 |
| Yoshimura, M | 2 |
| Ozaki, T | 1 |
| Takei, M | 1 |
| Tanaka, T | 1 |
| Li, HL | 1 |
| Lu, L | 1 |
| Wang, XS | 1 |
| Qin, LY | 1 |
| Wang, P | 1 |
| Qiu, SP | 1 |
| Huang, F | 1 |
| Zhang, BB | 1 |
| Shi, HL | 1 |
| Wu, XJ | 1 |
| Trindade, LM | 1 |
| Martins, VD | 1 |
| Rodrigues, NM | 1 |
| Souza, ELS | 1 |
| Martins, FS | 1 |
| Costa, GMF | 1 |
| Almeida-Leite, CM | 1 |
| Faria, AMC | 1 |
| Cardoso, VN | 3 |
| Maioli, TU | 1 |
| Generoso, SV | 2 |
| de Barros, PAV | 1 |
| Rabelo Andrade, ME | 1 |
| de Vasconcelos Generoso, S | 1 |
| Mendes Miranda, SE | 1 |
| Dos Reis, DC | 1 |
| Lacerda Leocádio, PC | 1 |
| de Sales E Souza, ÉL | 2 |
| Dos Santos Martins, F | 1 |
| da Gama, MAS | 1 |
| Cassali, GD | 1 |
| Alvarez Leite, JI | 1 |
| Antunes Fernandes, SO | 1 |
| Dougherty, JP | 1 |
| Springer, DA | 1 |
| Cullen, MJ | 1 |
| Gershengorn, MC | 1 |
| Innominato, P | 1 |
| Komarzynski, S | 1 |
| Karaboué, A | 1 |
| Ulusakarya, A | 1 |
| Bouchahda, M | 1 |
| Haydar, M | 1 |
| Bossevot-Desmaris, R | 1 |
| Mocquery, M | 1 |
| Plessis, V | 1 |
| Lévi, F | 1 |
| Fukuno, S | 1 |
| Nagai, K | 1 |
| Fujiike, M | 1 |
| Sasaki, Y | 1 |
| Konishi, H | 1 |
| Alinca, SB | 1 |
| Saglam, E | 1 |
| Kandas, NO | 1 |
| Okcu, O | 1 |
| Yilmaz, N | 1 |
| Goncu, B | 1 |
| Dogan, MA | 1 |
| Zhang, L | 1 |
| Jin, Y | 1 |
| Peng, J | 1 |
| Chen, W | 1 |
| Lisha, L | 1 |
| Lin, J | 1 |
| Winocur, G | 1 |
| Wojtowicz, JM | 1 |
| Huang, J | 1 |
| Tannock, IF | 2 |
| Yuan, KT | 1 |
| Yu, HL | 1 |
| Feng, WD | 1 |
| Chong, P | 1 |
| Yang, T | 1 |
| Xue, CL | 1 |
| Yu, M | 1 |
| Shi, HP | 1 |
| Hayashi, S | 1 |
| Kitahara, Y | 1 |
| Nagasawa, K | 1 |
| Aono, H | 1 |
| Shibata, J | 1 |
| Utsumi, D | 1 |
| Kadowaki, M | 1 |
| Araújo, CV | 1 |
| Lazzarotto, CR | 1 |
| Aquino, CC | 1 |
| Figueiredo, IL | 1 |
| Costa, TB | 1 |
| Alves, LA | 1 |
| Ribeiro, RA | 1 |
| Bertolini, LR | 1 |
| Lima, AA | 2 |
| Brito, GA | 2 |
| Oriá, RB | 2 |
| Kawashima, R | 1 |
| Fujimaki, M | 1 |
| Ikenoue, Y | 1 |
| Danjo, K | 1 |
| Koizumi, W | 1 |
| Ichikawa, T | 1 |
| Sun, Y | 1 |
| Zhou, J | 1 |
| Huang, Z | 1 |
| Hu, H | 2 |
| Qiao, M | 1 |
| Chen, D | 1 |
| Singh, S | 1 |
| Kotla, NG | 1 |
| Tomar, S | 1 |
| Maddiboyina, B | 1 |
| Webster, TJ | 1 |
| Sharma, D | 1 |
| Sunnapu, O | 1 |
| Forsgård, RA | 1 |
| Korpela, R | 1 |
| Holma, R | 1 |
| Lindén, J | 1 |
| Frias, R | 1 |
| Spillmann, T | 1 |
| Österlund, P | 1 |
| Barros, PA | 1 |
| Andrade, ME | 1 |
| da Gama, MA | 1 |
| Lopes, FC | 1 |
| Martins, FD | 1 |
| Miranda, SE | 1 |
| Fernandes, SO | 1 |
| Bernhard, J | 1 |
| Dietrich, D | 1 |
| Scheithauer, W | 1 |
| Gerber, D | 1 |
| Bodoky, G | 1 |
| Ruhstaller, T | 1 |
| Glimelius, B | 3 |
| Bajetta, E | 1 |
| Schüller, J | 1 |
| Saletti, P | 1 |
| Bauer, J | 1 |
| Figer, A | 1 |
| Pestalozzi, BC | 1 |
| Köhne, CH | 1 |
| Mingrone, W | 1 |
| Stemmer, SM | 1 |
| Tàmas, K | 1 |
| Kornek, GV | 1 |
| Koeberle, D | 1 |
| Herrmann, R | 1 |
| Zhang, Y | 1 |
| Chen, J | 1 |
| Liang, D | 1 |
| Yuan, Y | 1 |
| Smith, CL | 1 |
| Geier, MS | 2 |
| Yazbeck, R | 3 |
| Torres, DM | 1 |
| Butler, RN | 4 |
| Howarth, GS | 4 |
| Perboni, S | 1 |
| Bowers, C | 1 |
| Kojima, S | 2 |
| Asakawa, A | 1 |
| Inui, A | 1 |
| Xue, H | 1 |
| Le Roy, S | 1 |
| Sawyer, MB | 1 |
| Field, CJ | 1 |
| Dieleman, LA | 1 |
| Baracos, VE | 1 |
| Whitford, EJ | 2 |
| Cummins, AG | 2 |
| Prisciandaro, LD | 2 |
| Fauser, JK | 2 |
| Lawrence, A | 2 |
| Cheah, KY | 2 |
| Wright, TH | 2 |
| Lymn, KA | 2 |
| El-Sayyad, HI | 1 |
| Ismail, MF | 1 |
| Shalaby, FM | 1 |
| Abou-El-Magd, RF | 1 |
| Gaur, RL | 1 |
| Fernando, A | 1 |
| Raj, MH | 1 |
| Ouhtit, A | 1 |
| Ozel, L | 1 |
| Ozel, MS | 1 |
| Toros, AB | 1 |
| Kara, M | 1 |
| Ozkan, KS | 1 |
| Tellioglu, G | 1 |
| Krand, O | 1 |
| Koyuturk, M | 1 |
| Berber, I | 1 |
| Uludag, M | 1 |
| Ozdilli, K | 1 |
| Citgez, B | 1 |
| Yetkin, G | 1 |
| Ipcioglu, OM | 1 |
| Ozcan, O | 1 |
| Polat, N | 1 |
| Kartal, A | 1 |
| Torun, P | 1 |
| Isgor, A | 1 |
| Hasenberg, T | 1 |
| Essenbreis, M | 1 |
| Herold, A | 1 |
| Post, S | 1 |
| Shang, E | 1 |
| Chen, YW | 1 |
| Lin, GJ | 1 |
| Chuang, YP | 1 |
| Chia, WT | 1 |
| Hueng, DY | 1 |
| Lin, CK | 1 |
| Nieh, S | 1 |
| Sytwu, HK | 1 |
| Wang, GP | 1 |
| Guan, YS | 1 |
| Jin, XR | 1 |
| Jiang, SS | 1 |
| Lu, ZJ | 1 |
| Li, Y | 1 |
| Li, M | 1 |
| Luo, F | 1 |
| Wu, Z | 2 |
| Han, X | 2 |
| Qin, S | 2 |
| Zheng, Q | 2 |
| Wang, Z | 2 |
| Xiang, D | 2 |
| Wu, M | 2 |
| Zhu, S | 2 |
| Yu, Y | 2 |
| Han, W | 2 |
| Ferrucci, LM | 1 |
| Bell, D | 1 |
| Thornton, J | 1 |
| Black, G | 1 |
| McCorkle, R | 1 |
| Heimburger, DC | 1 |
| Saif, MW | 1 |
| Thomas, AM | 1 |
| Kapanen, AI | 1 |
| Hare, JI | 1 |
| Ramsay, E | 1 |
| Edwards, K | 1 |
| Karlsson, G | 1 |
| Bally, MB | 1 |
| Walker, EA | 1 |
| Foley, JJ | 1 |
| Clark-Vetri, R | 1 |
| Raffa, RB | 1 |
| Pellen, MG | 1 |
| Sabri, S | 1 |
| Razack, A | 1 |
| Gilani, SQ | 1 |
| Jain, PK | 1 |
| Shibayama, Y | 1 |
| Iwashita, Y | 1 |
| Yoshikawa, Y | 1 |
| Kondo, T | 2 |
| Ikeda, R | 1 |
| Takeda, Y | 1 |
| Osada, T | 1 |
| Sugawara, M | 1 |
| Yamada, K | 2 |
| Iseki, K | 1 |
| Lyons, L | 1 |
| ElBeltagy, M | 1 |
| Bennett, G | 1 |
| Wigmore, P | 1 |
| Jin, K | 1 |
| Lan, H | 1 |
| Xie, B | 1 |
| He, K | 1 |
| Xu, Z | 1 |
| Li, G | 1 |
| Han, N | 1 |
| Teng, L | 1 |
| Cao, F | 1 |
| Cao, Z | 1 |
| Liao, L | 1 |
| Chen, X | 1 |
| Lan, L | 1 |
| Liu, Z | 1 |
| Chen, L | 1 |
| Huang, S | 1 |
| Du, J | 1 |
| Sakai, H | 1 |
| Sagara, A | 1 |
| Hasegawa, S | 2 |
| Sato, K | 2 |
| Nishizaki, M | 1 |
| Shoji, T | 1 |
| Horie, S | 1 |
| Nakagawa, T | 1 |
| Tokuyama, S | 1 |
| Narita, M | 1 |
| Gusella, M | 1 |
| Toso, S | 1 |
| Ferrazzi, E | 1 |
| Ferrari, M | 1 |
| Padrini, R | 1 |
| Fan, YF | 1 |
| Huang, ZH | 1 |
| Nie, J | 1 |
| Takaba, K | 1 |
| Kimoto, N | 1 |
| Takeda, T | 1 |
| Kakuni, M | 1 |
| Mizutani, M | 1 |
| Suzuki, K | 1 |
| Sato, H | 1 |
| Hara, T | 1 |
| Mori, T | 2 |
| Fujiwara, Y | 1 |
| Yano, M | 1 |
| Tamura, S | 1 |
| Yasuda, T | 1 |
| Takiguchi, S | 1 |
| Monden, M | 1 |
| Meyerhardt, JA | 1 |
| Catalano, PJ | 1 |
| Haller, DG | 1 |
| Mayer, RJ | 1 |
| Benson, AB | 1 |
| Macdonald, JS | 1 |
| Fuchs, CS | 1 |
| Von Bültzingslöwen, I | 1 |
| Adlerberth, I | 1 |
| Wold, AE | 1 |
| Dahlén, G | 1 |
| Jontell, M | 1 |
| Hironaka, S | 1 |
| Ohtsu, A | 1 |
| Boku, N | 1 |
| Muto, M | 1 |
| Nagashima, F | 1 |
| Saito, H | 1 |
| Yoshida, S | 1 |
| Nishimura, M | 1 |
| Haruno, M | 1 |
| Ishikura, S | 1 |
| Ogino, T | 1 |
| Yamamoto, S | 1 |
| Ochiai, A | 1 |
| Iba, T | 1 |
| Kidokoro, A | 1 |
| Fukunaga, M | 1 |
| Sugiyama, K | 1 |
| Fukunaga, T | 1 |
| Aihara, N | 1 |
| Clavijo, J | 1 |
| Gomez-de-Segura, IA | 1 |
| Gomez-García, L | 1 |
| Vallejo-Cremades, MT | 1 |
| Sanchez, M | 1 |
| de Miguel, E | 1 |
| Goto, T | 2 |
| Tomizawa, N | 1 |
| Kobayashi, E | 1 |
| Fujimura, A | 1 |
| Aksungur, P | 1 |
| Sungur, A | 1 |
| Unal, S | 1 |
| Iskit, AB | 1 |
| Squier, CA | 1 |
| Senel, S | 1 |
| Carneiro-Filho, BA | 1 |
| Wood Rea, K | 1 |
| Fujii, J | 1 |
| Obrig, T | 1 |
| Guerrant, RL | 1 |
| Cool, JC | 1 |
| Dyer, JL | 1 |
| Xian, CJ | 1 |
| Al Safarjalani, ON | 2 |
| Zhou, XJ | 1 |
| Rais, RH | 1 |
| Shi, J | 2 |
| Schinazi, RF | 2 |
| Naguib, FN | 2 |
| El Kouni, MH | 2 |
| Xu, Q | 1 |
| Brabham, JG | 1 |
| Zhang, S | 1 |
| Munster, P | 1 |
| Fields, K | 1 |
| Zhao, RJ | 1 |
| Yu, H | 1 |
| Tjomsland, V | 2 |
| El-Salhy, M | 2 |
| Ewens, AD | 1 |
| Mihich, E | 1 |
| Ehrke, MJ | 1 |
| Hilding, L | 1 |
| Royson, H | 1 |
| Barletta, E | 1 |
| Fiore, F | 1 |
| Daniele, B | 1 |
| Ottaiano, A | 1 |
| D'Angelo, R | 1 |
| Ferrari, E | 1 |
| Formato, R | 1 |
| Tortoriello, A | 1 |
| Turitto, G | 1 |
| Bruni, GS | 1 |
| Pignata, S | 1 |
| Iaffaioli, RV | 1 |
| Yurimoto, S | 1 |
| Miyakawa, A | 1 |
| Okuzawa, A | 1 |
| Sakamoto, S | 2 |
| Sakamoto, K | 1 |
| Hosoda, S | 1 |
| Kamano, T | 1 |
| Moriyama, K | 1 |
| Kouchi, Y | 2 |
| Morinaga, H | 2 |
| Irimura, K | 1 |
| Hayashi, T | 1 |
| Ohuchida, A | 2 |
| Yoshizawa, Y | 1 |
| Rais, R | 1 |
| Mitsuhashi, H | 1 |
| Suemaru, K | 1 |
| Li, B | 1 |
| Cui, R | 1 |
| Araki, H | 1 |
| Allen, AM | 1 |
| Elshaikh, M | 1 |
| Worden, FP | 1 |
| Bradford, CR | 1 |
| Teknos, TN | 1 |
| Chepeha, DB | 1 |
| Tsien, C | 1 |
| Dawson, LA | 1 |
| Urba, S | 1 |
| Wolf, GT | 1 |
| Normolle, D | 1 |
| Eisbruch, A | 1 |
| Rajeshkumar, NV | 1 |
| Matwyshyn, G | 1 |
| Gulati, A | 1 |
| Hung, H | 1 |
| Manzano, M | 1 |
| Bueno, P | 1 |
| Rueda, R | 1 |
| Ramirez-Tortosa, CL | 1 |
| Prieto, PA | 1 |
| Lopez-Pedrosa, JM | 1 |
| Poujol, S | 1 |
| Pinguet, F | 1 |
| Ychou, M | 1 |
| Abderrahim, AG | 1 |
| Duffour, J | 1 |
| Bressolle, FM | 1 |
| Xu, ZL | 1 |
| Zhou, B | 1 |
| Cong, XL | 1 |
| Liu, YJ | 1 |
| Xu, B | 1 |
| Li, YH | 1 |
| Gu, J | 1 |
| Han, ZC | 1 |
| Melvin, JB | 1 |
| Burchenal, JH | 1 |
| Dollinger, M | 1 |
| Butterbaugh, J | 1 |
| Stoll, D | 1 |
| Giner-Sorolla, A | 1 |
| Falkson, G | 1 |
| MacIntyre, JM | 1 |
| Moertel, CG | 1 |
| Johnson, LA | 1 |
| Scherman, RC | 1 |
| Schouwenburg, PF | 1 |
| Van Putten, LM | 2 |
| Snow, GB | 1 |
| Hughes, KB | 1 |
| Engelbrecht, C | 1 |
| Ljungquist, I | 1 |
| Lewan, L | 1 |
| Yngner, T | 1 |
| Yamada, N | 1 |
| Koyama, H | 1 |
| Hioki, K | 1 |
| Yamada, T | 1 |
| Yamamoto, M | 1 |
| Hirayama, R | 1 |
| Hamada, S | 1 |
| Matsumura, J | 1 |
| Takagi, Y | 1 |
| Miyanaga, T | 1 |
| Aoki, N | 1 |
| Mishima, Y | 1 |
| Mori, H | 3 |
| Nakatomi, I | 1 |
| Kato, Y | 3 |
| Koda, A | 2 |
| Kreuter, J | 1 |
| Hartmann, HR | 1 |
| Nuutinen, LS | 1 |
| Kauppila, A | 1 |
| Ryhänen, P | 1 |
| Niinimäki, A | 1 |
| Kivinen, S | 1 |
| Saarela, M | 1 |
| Pakarinen, A | 1 |
| Hollmén, A | 1 |
| Okajima, E | 2 |
| Hiramatsu, T | 2 |
| Kihoin, K | 1 |
| Ijuin, M | 1 |
| Hirao, Y | 2 |
| Ohara, S | 1 |
| Babaya, K | 1 |
| Tanaka, M | 3 |
| Maruyama, Y | 1 |
| Kasai, Y | 1 |
| Inokuchi, K | 1 |
| Hattori, T | 2 |
| Inoue, K | 1 |
| Taguchi, T | 4 |
| Akiyama, H | 1 |
| Abe, O | 1 |
| Ito, I | 1 |
| Nakajima, T | 1 |
| Muto, T | 1 |
| Kikuchi, K | 1 |
| Sugie, S | 1 |
| Hayasaka, A | 1 |
| Slørdal, L | 1 |
| Høyem-Johansen, T | 1 |
| Aarbakke, J | 1 |
| Lee, YT | 1 |
| Mulder, JH | 1 |
| Smink, T | 1 |
| Chlebowski, RT | 3 |
| Heber, D | 1 |
| Popovic, P | 1 |
| Popovic, V | 1 |
| Baughman, J | 1 |
| Miccolis, N | 1 |
| Gardner, ML | 2 |
| Plumb, JA | 1 |
| Smith, WE | 1 |
| Hubert, DD | 1 |
| Holiat, SM | 1 |
| Sobel, HJ | 1 |
| Davis, S | 1 |
| Kato, T | 2 |
| Kakinuma, H | 1 |
| Matsuda, Y | 1 |
| Futamura, Y | 1 |
| Van der Wilt, CL | 1 |
| Braakhuis, BJ | 1 |
| Pinedo, HM | 1 |
| De Jong, M | 1 |
| Smid, K | 1 |
| Peters, GJ | 1 |
| Sato, T | 1 |
| Shakil, A | 1 |
| Hirabayashi, N | 2 |
| Toge, T | 1 |
| Motoyama, M | 1 |
| Imaoka, T | 1 |
| Ichihara, N | 1 |
| Miyauchi, S | 2 |
| Graf, W | 2 |
| Weiber, S | 2 |
| Jiborn, H | 2 |
| Påhlman, L | 2 |
| Zederfeldt, B | 2 |
| Mizuno, M | 1 |
| Kudo, H | 1 |
| Suzuki, S | 2 |
| Kasahara, N | 1 |
| Sugiura, Y | 1 |
| Nagasawa, H | 1 |
| Watanabe, S | 1 |
| Sato, S | 1 |
| Nagase, S | 1 |
| Saito, T | 1 |
| Fujita, F | 2 |
| Fujita, M | 3 |
| Sakamoto, Y | 1 |
| Inaba, H | 1 |
| Singh, G | 1 |
| Graffner, HO | 1 |
| Milsom, JW | 1 |
| Chaudry, IH | 1 |
| Ashizawa, T | 1 |
| Ishida, H | 1 |
| Okabe, M | 1 |
| Gomi, K | 1 |
| Sundaram, SG | 1 |
| Milner, JA | 1 |
| Findlay, M | 1 |
| Young, H | 1 |
| Cunningham, D | 1 |
| Iveson, A | 1 |
| Cronin, B | 1 |
| Hickish, T | 1 |
| Pratt, B | 1 |
| Husband, J | 1 |
| Flower, M | 1 |
| Ott, R | 1 |
| de Waard, JW | 1 |
| Wobbes, T | 4 |
| de Man, BM | 1 |
| van der Linden, CJ | 1 |
| Hendriks, T | 4 |
| Rothenberg, ML | 1 |
| Moore, MJ | 1 |
| Cripps, MC | 1 |
| Andersen, JS | 1 |
| Portenoy, RK | 1 |
| Burris, HA | 1 |
| Green, MR | 1 |
| Tarassoff, PG | 1 |
| Brown, TD | 1 |
| Casper, ES | 1 |
| Storniolo, AM | 1 |
| Von Hoff, DD | 1 |
| Rosner, GL | 1 |
| Hargis, JB | 1 |
| Hollis, DR | 1 |
| Budman, DR | 1 |
| Weiss, RB | 1 |
| Henderson, IC | 1 |
| Schilsky, RL | 1 |
| Hagiwara, A | 1 |
| Sakakura, C | 1 |
| Tsujimoto, H | 1 |
| Ohgaki, M | 1 |
| Imanishi, T | 1 |
| Yamazaki, J | 1 |
| Sawai, K | 1 |
| Takahashi, T | 2 |
| Yamamoto, A | 2 |
| Muranishi, S | 1 |
| Tabata, Y | 1 |
| Ikada, Y | 1 |
| Shibamoto, Y | 1 |
| Murata, R | 1 |
| Hirohashi, M | 1 |
| Takagi, T | 1 |
| Sasai, K | 1 |
| Shibata, T | 1 |
| Oya, N | 1 |
| Takahashi, M | 1 |
| Maeda, Y | 1 |
| Biert, J | 1 |
| Hoogenhout, J | 1 |
| de Man, B | 1 |
| Matsuda, A | 1 |
| Higuchi, K | 1 |
| Karasawa, M | 1 |
| Yoneyama, S | 1 |
| Deguchi, J | 1 |
| Miyamoto, M | 1 |
| Tateishi, T | 2 |
| Watanabe, M | 2 |
| Nakura, H | 2 |
| Kumai, T | 2 |
| Kobayashi, S | 2 |
| Sharma, R | 1 |
| Adam, E | 1 |
| Schumacher, U | 1 |
| Tanaka, H | 1 |
| Miyamoto, KI | 1 |
| Morita, K | 1 |
| Haga, H | 1 |
| Segawa, H | 1 |
| Shiraga, T | 1 |
| Fujioka, A | 1 |
| Kouda, T | 1 |
| Taketani, Y | 1 |
| Hisano, S | 1 |
| Fukui, Y | 1 |
| Kitagawa, K | 1 |
| Takeda, E | 1 |
| Murakami, Y | 1 |
| Fujii, H | 1 |
| Ichimura, A | 1 |
| Murata, A | 1 |
| Yamashita, N | 1 |
| Takagi, H | 1 |
| Tauchi, K | 1 |
| Elekes, E | 1 |
| Bertók, L | 1 |
| Cao, S | 1 |
| Frank, C | 1 |
| Shirasaka, T | 1 |
| Rustum, YM | 2 |
| Murakami, K | 1 |
| Matsuura, T | 1 |
| Sano, M | 1 |
| Hashimoto, A | 1 |
| Yonekura, K | 1 |
| Sakukawa, R | 1 |
| Yamada, Y | 1 |
| Saiki, I | 1 |
| Cascinu, S | 1 |
| Frontini, L | 1 |
| Comella, G | 1 |
| Barni, S | 1 |
| Labianca, R | 1 |
| Battelli, N | 1 |
| Casaretti, R | 1 |
| Zonato, S | 1 |
| Pirovano, M | 1 |
| Catalano, G | 1 |
| Cellerino, R | 1 |
| Rudolph, KL | 1 |
| Chang, S | 1 |
| Lee, HW | 1 |
| Blasco, M | 1 |
| Gottlieb, GJ | 1 |
| Greider, C | 1 |
| DePinho, RA | 1 |
| Sakata, SF | 1 |
| Tamaki, N | 1 |
| Ogura, K | 1 |
| Nishiyama, T | 1 |
| Watabe, T | 1 |
| Hirata, K | 1 |
| Horie, T | 1 |
| Endo, M | 2 |
| Shinbori, N | 1 |
| Fukase, Y | 1 |
| Sawada, N | 1 |
| Ishikawa, T | 1 |
| Ishitsuka, H | 1 |
| Liu, J | 1 |
| Skradis, A | 1 |
| Kolar, C | 1 |
| Kolath, J | 1 |
| Anderson, J | 1 |
| Lawson, T | 1 |
| Talmadge, J | 1 |
| Gmeiner, WH | 1 |
| Deng, GY | 1 |
| Liu, YW | 1 |
| He, GZ | 1 |
| Jiang, ZM | 1 |
| Mitsuyama, S | 1 |
| Ohno, S | 1 |
| Koga, T | 1 |
| Takayama, T | 2 |
| Yamashita, J | 1 |
| Ogawa, M | 1 |
| Shirouzu, K | 1 |
| Sugimachi, K | 1 |
| Nomura, Y | 1 |
| Ogawa, N | 1 |
| Satoh, H | 1 |
| Ohtomo, M | 1 |
| Ishikawa, H | 1 |
| Kamma, H | 1 |
| Ohtsuka, M | 1 |
| Tavakkolizadeh, A | 1 |
| Shen, R | 1 |
| Abraham, P | 1 |
| Kormi, N | 1 |
| Seifert, P | 1 |
| Edelman, ER | 1 |
| Jacobs, DO | 1 |
| Zinner, MJ | 1 |
| Ashley, SW | 1 |
| Whang, EE | 1 |
| Kinuya, S | 1 |
| Yokoyama, K | 1 |
| Konishi, S | 1 |
| Watanabe, N | 2 |
| Shuke, N | 1 |
| Aburano, T | 1 |
| Michigishi, T | 1 |
| Tonami, N | 1 |
| Yoshisue, K | 1 |
| Hironaga, K | 1 |
| Yamaguchi, S | 1 |
| Nagayama, S | 1 |
| Kawaguchi, Y | 1 |
| Honda, K | 1 |
| Ishida, R | 1 |
| Nohira, T | 1 |
| Tomoda, A | 1 |
| Takiguchi, N | 1 |
| Saito, N | 1 |
| Nunomura, M | 1 |
| Kouda, K | 1 |
| Oda, K | 1 |
| Furuyama, N | 1 |
| Nakajima, N | 1 |
| Furukawa, M | 1 |
| Karakama, T | 1 |
| Kaji, M | 1 |
| Gomita, S | 1 |
| Inomata, A | 1 |
| Matsumoto, H | 1 |
| Horii, I | 2 |
| Sommer, K | 1 |
| Peters, SO | 1 |
| Robins, IH | 1 |
| Raap, M | 1 |
| Wiedemann, GJ | 1 |
| Remmert, S | 1 |
| Sieg, P | 1 |
| Bittner, C | 1 |
| Feyerabend, T | 1 |
| Haciyanli, M | 1 |
| Fuzun, M | 1 |
| Unek, T | 1 |
| Tokgoz, Z | 1 |
| El-Malt, M | 1 |
| Ceelen, W | 1 |
| van den Broecke, C | 1 |
| Cuvelier, C | 1 |
| Van Belle, S | 1 |
| De Neve, W | 1 |
| de Hemptinne, B | 1 |
| Pattyn, P | 1 |
| Makino, M | 1 |
| Shoji, H | 1 |
| Takemoto, D | 1 |
| Honboh, T | 1 |
| Nakamura, S | 1 |
| Kurayoshi, K | 1 |
| Kaibara, N | 1 |
| Xiao, HB | 1 |
| Cao, WX | 1 |
| Yin, HR | 1 |
| Lin, YZ | 1 |
| Ye, SH | 1 |
| Inoue, T | 1 |
| Kohlschütter, B | 1 |
| Jehn, U | 1 |
| Forsthoefel, PF | 1 |
| Williams, ML | 1 |
| Houghton, JA | 1 |
| Houghton, PJ | 1 |
| Wooten, RS | 1 |
| Spiro, SG | 1 |
| Charman, J | 1 |
| Das, I | 1 |
| Reid, L | 1 |
| Pallavicini, MG | 1 |
| Cohen, AM | 1 |
| Dethlefsen, LA | 1 |
| Gray, JW | 1 |
| Hortobagyi, GN | 1 |
| Blumenschein, GR | 1 |
| Tashima, CK | 1 |
| Buzdar, AU | 1 |
| Burgess, MA | 1 |
| Livingston, RB | 1 |
| Valdivieso, M | 1 |
| Gutterman, JU | 1 |
| Hersh, EM | 1 |
| Bodey, GP | 1 |
| Fernandes, DJ | 1 |
| Klubes, P | 2 |
| Ryan, CJ | 1 |
| Ryan, S | 1 |
| Wood, CB | 1 |
| Blumgart, LH | 1 |
| Basu, TK | 1 |
| Aksoy, M | 1 |
| Dickerson, JW | 2 |
| Poole, TW | 1 |
| Dunbar, SF | 1 |
| Heading, RC | 1 |
| Stanford, JR | 1 |
| King, D | 1 |
| Carey, L | 1 |
| Anderson, G | 1 |
| Nagasue, N | 1 |
| Kobayashi, M | 1 |
| Iwaki, A | 1 |
| Yukaya, H | 1 |
| Kanashima, R | 1 |
| Inokughi, K | 1 |
| Ogiso, T | 2 |
| Noda, N | 2 |
| Masuda, H | 1 |
| Bounous, G | 2 |
| Pageau, R | 1 |
| Regoli, D | 1 |
| Copeland, EM | 2 |
| MacFadyen, BV | 1 |
| Lanzotti, VJ | 1 |
| Dudrick, SJ | 2 |
| Steiger, E | 1 |
| Oram-Smith, J | 1 |
| Miller, E | 1 |
| Kuo, L | 1 |
| Vars, HM | 1 |
| Schmidt, JD | 1 |
| Gibbons, RP | 1 |
| Johnson, DE | 1 |
| Prout, GR | 1 |
| Scott, WW | 2 |
| Murphy, GP | 1 |
| Asai, N | 1 |
| Povlsen, CO | 1 |
| Jacobsen, GK | 1 |
| Bailly, C | 1 |
| Collyn-d'Hooghe, M | 1 |
| Lantoine, D | 1 |
| Fournier, C | 1 |
| Hecquet, B | 1 |
| Fosse, P | 1 |
| Saucier, JM | 1 |
| Colson, P | 1 |
| Houssier, C | 1 |
| Hénichart, JP | 1 |
| Nord, LD | 1 |
| Stolfi, RL | 2 |
| Martin, DS | 2 |
| Sakamoto, O | 1 |
| Kitaichi, K | 1 |
| de Roy van Zuidewijn, DB | 2 |
| de Boer, HH | 2 |
| Subramaniam, S | 1 |
| Marar, T | 1 |
| Devi, CS | 1 |
| Goseki, N | 1 |
| Onodera, T | 1 |
| Kosaki, G | 1 |
| Salm, R | 1 |
| Wullich, B | 1 |
| Kiefer, G | 1 |
| Fiebig, HH | 1 |
| Farthmann, EH | 1 |
| Ouchi, T | 1 |
| Banba, T | 1 |
| Matsumoto, T | 1 |
| Suzuki, M | 1 |
| Kusuyama, T | 1 |
| Okuyama, Y | 1 |
| O'Reilly, M | 1 |
| Gamelli, RL | 1 |
| Torosian, MH | 1 |
| Jalali, S | 1 |
| Nguyen, HQ | 1 |
| Naya, M | 1 |
| Noguchi, M | 1 |
| Mataki, Y | 1 |
| Deguchi, T | 1 |
| Yasuda, M | 1 |
| Klompmakers, AA | 1 |
| Fujimoto, S | 1 |
| Igarashi, K | 1 |
| Shrestha, RD | 1 |
| Miyazaki, M | 1 |
| Endoh, F | 1 |
| Ohta, M | 1 |
| Togawa, Y | 1 |
| Okui, K | 1 |
| Au, JL | 1 |
| Slocum, HK | 1 |
| Nishiyama, M | 1 |
| Takagami, S | 1 |
| Kirihara, Y | 1 |
| Saeki, T | 1 |
| Nosoh, Y | 1 |
| Niimoto, M | 1 |
| Takao, S | 1 |
| Ishizawa, T | 1 |
| Shimazu, H | 1 |
| Ozono, S | 1 |
| Iwata, H | 1 |
| Tsunemi, K | 1 |
| Takahashi, S | 1 |
| Matsuki, H | 1 |
| Sasaki, K | 1 |
| Powis, G | 1 |
| Reece, P | 1 |
| Ahmann, DL | 1 |
| Ingle, JN | 1 |
| Hillan, K | 1 |
| Nordlinger, B | 1 |
| Ballet, F | 1 |
| Puts, JP | 1 |
| Infante, R | 1 |
| Goodwin, PJ | 1 |
| Panzarella, T | 1 |
| Boyd, NF | 2 |
| Fu, NW | 1 |
| Zhang, LS | 1 |
| Quan, LP | 1 |
| Guo, R | 1 |
| Kitahara, M | 1 |
| Katakura, R | 1 |
| Suzuki, J | 1 |
| Sasaki, T | 1 |
| Weiner, JM | 2 |
| Reynolds, R | 1 |
| Luce, J | 1 |
| Bulcavage, L | 1 |
| Bateman, JR | 2 |
| Murata, T | 1 |
| Robbins, TJ | 1 |
| Bowen, D | 1 |
| Bui, QQ | 1 |
| Tran, MT | 1 |
| Knobf, MT | 1 |
| Gregory, EJ | 1 |
| Cohen, SC | 1 |
| Oines, DW | 1 |
| Mims, CH | 1 |
| Huntington, MO | 1 |
| Silverberg, I | 1 |
| Glass, A | 1 |
| Darnowski, JW | 1 |
| Sawyer, RC | 1 |
| Lau-Cam, CA | 1 |
| Rich, TA | 1 |
| Lokich, JJ | 1 |
| Chaffey, JT | 1 |
| Heasman, KZ | 1 |
| Sutherland, HJ | 1 |
| Campbell, JA | 1 |
| Elhakim, T | 1 |
| Balnave, D | 1 |
| Pearce, J | 1 |
| Macfayden, BV | 1 |
| Williams, JP | 1 |
| Frankfurt, OS | 1 |
| White, WD | 1 |
| Juniper, K | 1 |
| Muratova, GP | 1 |
| Mal'tseva, LF | 1 |
| Rudzit, EA | 1 |
| Wong, KH | 1 |
| Miller, CE | 1 |
| Feeley, JC | 1 |
| Chan, YK | 1 |
| Walker, EM | 1 |
| Gale, GR | 1 |
| Cerna, I | 1 |
| Schwartz, GF | 1 |
| Green, HL | 1 |
| Bendon, ML | 1 |
| Graham, WP | 1 |
| Blakemore, WS | 1 |
| Hugon, J | 1 |
| Gentile, JM | 1 |
| Unemi, N | 1 |
| Harima, K | 1 |
| Daidai, Y | 1 |
| Fujihara, H | 1 |
| Fujii, S | 1 |
| Ringleb, D | 1 |
| Grundner, HG | 1 |
| Krieg, R | 1 |
| Steckenmesser, R | 1 |
| Hayashi, I | 1 |
| Yoshida, K | 1 |
| Hiasa, Y | 1 |
| Tamai, A | 1 |
| Ito, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer: FIRE-8; AIO-KRK/YMO-05[NCT05007132] | Phase 2 | 153 participants (Anticipated) | Interventional | 2021-12-17 | Recruiting | ||
| Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Domomedecine Plateform[NCT04263948] | 42 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | |||
| Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial[NCT00030732] | Phase 3 | 319 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial[NCT00073905] | Phase 2 | 44 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802] | 190 participants (Anticipated) | Observational | 2016-10-06 | Recruiting | |||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer[NCT00589901] | Phase 2 | 60 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 trials available for fluorouracil and Body Weight
| Article | Year |
|---|---|
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line tre
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev | 2022 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomize
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body W | 2010 |
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Capecitabine; Combined Modal | 2011 |
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; Chemotherapy, Adjuvant | 2003 |
Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies.
Topics: Adult; Animals; Antifungal Agents; Biological Availability; Body Weight; Chitosan; Cricetinae; Cross | 2004 |
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; | 2007 |
Primary liver cancer. An Eastern Cooperative Oncology Group Trial.
Topics: Adenoma, Bile Duct; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body W | 1984 |
Effect of postoperative total parenteral nutrition (TPN) as an adjunct to gastrectomy for advanced gastric carcinoma.
Topics: Adult; Aged; Antibody Formation; Blood Proteins; Body Weight; Fluorouracil; Gastrectomy; Humans; Imm | 1983 |
Intensified nutrition as an adjunct to cytotoxic chemotherapy in gynaecological cancer patients.
Topics: Antineoplastic Agents; Body Weight; Cisplatin; Cyclophosphamide; Cystadenocarcinoma; Doxorubicin; Dr | 1982 |
[Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)].
Topics: Aged; Antibiotics, Antineoplastic; Blood Cell Count; Body Weight; Clinical Trials as Topic; Drug The | 1982 |
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Pr | 1996 |
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Chemotherapy, Adjuvan | 1996 |
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma; Cisplatin; Drug Admini | 1999 |
[Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Cyclopho | 1999 |
Chemotherapy of advanced prostatic cancer. Evaluation of response parameters.
Topics: Aged; Body Weight; Bone Marrow Examination; Bone Neoplasms; Cyclophosphamide; Drug Evaluation; Fluor | 1976 |
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; | 1987 |
Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Clinical Trials as To | 1986 |
Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma.
Topics: Adenocarcinoma; Aged; Body Weight; Clinical Trials as Topic; Cyclophosphamide; Drug Administration S | 1985 |
214 other studies available for fluorouracil and Body Weight
| Article | Year |
|---|---|
Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Ce | 2009 |
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Body Weight; Cell Line, Tumor; Cell | 2015 |
Therapeutic Effects of GGsTop
Topics: Aminobutyrates; Animals; Antimetabolites, Antineoplastic; Body Weight; Collagen; Disease Models, Ani | 2021 |
ROS and iron homeostasis dependent ferroptosis play a vital role in 5-Fluorouracil induced cardiotoxicity in vitro and in vivo.
Topics: Animals; Blotting, Western; Body Weight; Coloring Agents; Creatine Kinase; Echocardiography; Eosine | 2022 |
Protective effect of polysaccharides isolated from the seeds of Cuscuta chinensis Lam. on 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Body Weight; Caspase 3; Cuscut | 2022 |
Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; Diarrhea; Doxorubicin; Fluorouracil; Idarubici | 2022 |
Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation.
Topics: Animals; Antineoplastic Agents; Body Weight; Butyrates; Cadherins; Claudin-1; Diarrhea; Drugs, Chine | 2022 |
Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Body Weight; Diarrhea; Dipeptidyl Pe | 2019 |
Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Cell Proliferation; | 2019 |
Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carbon-S | 2019 |
Nutritional treatment with an immune-modulating enteral formula alleviates 5-fluorouracil-induced adverse effects in rats.
Topics: Animals; Body Weight; Cultured Milk Products; Dietary Supplements; Disease Models, Animal; Eating; E | 2019 |
Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colorectal Neopl | 2019 |
A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Fluorouracil; Leukocyte Count; | 2020 |
The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Energy Metabolism; Fecal Microbiota Transplan | 2020 |
A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Body Weight; C | 2020 |
Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice.
Topics: Animals; Anti-Inflammatory Agents; Asteraceae; Body Weight; Cytokines; Diarrhea; Disease Models, Ani | 2021 |
Amelioration of 5-fluorouracil-induced intestinal mucositis by Streptococcus thermophilus ST4 in a mouse model.
Topics: Animals; Body Weight; Disease Models, Animal; Eating; Fluorouracil; Intestinal Mucosa; Male; Mice; M | 2021 |
Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses.
Topics: Animals; Apoptosis; Bifidobacterium bifidum; Body Weight; Diarrhea; Dysbiosis; Fluorouracil; Inflamm | 2017 |
The synergism and attenuation effect of Selenium (Se)-enriched Grifola frondosa (Se)-polysaccharide on 5-Fluorouracil (5-Fu) in Heps-bearing mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cell Proliferation; Drug Synergism; F | 2018 |
Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a.
Topics: Amides; Animals; Anorexia; Antineoplastic Agents; Body Weight; CHO Cells; Cisplatin; Cricetinae; Cri | 2018 |
Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis.
Topics: Animals; Antigens, CD; Bacteria; Body Weight; Cadherins; Cell Adhesion Molecules; Chemokines; Colon; | 2017 |
Oral administration of Simbioflora® (synbiotic) attenuates intestinal damage in a mouse model of 5-fluorouracil-induced mucositis.
Topics: Administration, Oral; Animals; Bifidobacterium animalis; Body Weight; Fatty Acids, Volatile; Feces; | 2018 |
Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model.
Topics: Animals; Bacterial Translocation; Body Weight; Chemokines; Disease Models, Animal; Feeding Behavior; | 2018 |
Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays.
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Behavior, Animal; Body Weight; Centr | 2019 |
Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Circadian Rhythm; Colorect | 2018 |
Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam.
Topics: Administration, Intravenous; Animals; Body Weight; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A In | 2019 |
Comparison of the efficacy of low-level laser therapy and photodynamic therapy on oral mucositis in rats.
Topics: Animals; Becaplermin; Body Weight; Fibroblast Growth Factor 2; Fluorouracil; Low-Level Light Therapy | 2019 |
Qingjie Fuzheng Granule attenuates 5-fluorouracil-induced intestinal mucosal damage.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Body Weight; Cell Proliferation; Diarrhea; Drugs, Ch | 2019 |
Physical exercise prevents suppression of hippocampal neurogenesis and reduces cognitive impairment in chemotherapy-treated rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cognition Disorders; Cues; Dentate Gyrus; Dou | 2014 |
Bifidobacterium infantis has a beneficial effect on 5-fluorouracil-induced intestinal mucositis in rats.
Topics: Animals; Bifidobacterium; Biomarkers; Body Weight; Fluorouracil; Immunohistochemistry; Intestinal Mu | 2015 |
Saireito (TJ-114), a Japanese traditional herbal medicine, reduces 5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis in intestinal crypt cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Body Weight; Caspase 3; Cytokines; Drugs, Chine | 2015 |
Alanyl-glutamine attenuates 5-fluorouracil-induced intestinal mucositis in apolipoprotein E-deficient mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apolipoproteins E; Apoptosis; Body Weight; Dipeptides; Fem | 2015 |
Influence of an elemental diet on 5-fluorouracil-induced morphological changes in the mouse salivary gland and colon.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Colon; Diarrhea; Disease Models, Anim | 2016 |
Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2015 |
A nanomedicine-promising approach to provide an appropriate colon-targeted drug delivery system for 5-fluorouracil.
Topics: Animals; Body Weight; Cecum; Colon; Diarrhea; Drug Delivery Systems; Drug Liberation; Female; Fluoro | 2015 |
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2016 |
Effect of Conjugated Linoleic Acid-enriched Butter After 24 hours of Intestinal Mucositis Induction.
Topics: Animals; Body Weight; Butter; Chemokines; Cytokines; Fluorouracil; Food, Fortified; Immunoglobulin A | 2017 |
Effects of human growth hormone on haematopoietic recovery of rats receiving chemotherapy.
Topics: Animals; Body Weight; Bone Marrow Cells; Carboplatin; Fluorouracil; Hematopoietic System; Human Grow | 2008 |
Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats.
Topics: Animals; Body Weight; Female; Fluorouracil; Jejunum; Limosilactobacillus fermentum; Mucositis; Oligo | 2008 |
Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice.
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Appetite Stimulants; Body Weight; Cachexia; Cell | 2008 |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colo
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Combined M | 2009 |
Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU).
Topics: Animals; Body Weight; Female; Fluorouracil; Injections, Intraperitoneal; Intestinal Mucosa; Jejunum; | 2009 |
Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats.
Topics: Animals; Antineoplastic Agents; Body Weight; Cisplatin; Doxorubicin; Fluorouracil; Liver; Male; Orga | 2009 |
Effect of early preoperative 5-fluorouracil on the integrity of colonic anastomoses in rats.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colorectal Neop | 2009 |
Covering the colon anastomoses with amniotic membrane prevents the negative effects of early intraperitoneal 5-FU administration on anastomotic healing.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Biological Dressings; Body Weight; | 2010 |
Triptolide circumvents drug-resistant effect and enhances 5-fluorouracil antitumor effect on KB cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2010 |
Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cell Line, Tumor; Chromatography, High Pressu | 2010 |
Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Body Weight; Diarrhea; Disease M | 2010 |
Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.
Topics: Animals; Biological Availability; Body Weight; Cell Survival; Cholesterol; DNA-Binding Proteins; Dru | 2011 |
Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Behavior, | 2011 |
Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; | 2012 |
Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-Fluorouracil in a mouse mucositis model.
Topics: Animals; Body Weight; Diarrhea; Disease Models, Animal; Drug Interactions; Female; Fluorouracil; Gen | 2011 |
Effect of 5-fluorouracil treatment on SN-38 absorption from intestine in rats.
Topics: Animals; ATP-Binding Cassette Transporters; Base Sequence; Body Weight; Camptothecin; Cell Line; DNA | 2011 |
Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery.
Topics: Animals; Antidepressive Agents, Second-Generation; Antimetabolites, Antineoplastic; Body Weight; Bro | 2012 |
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Carcinoma | 2012 |
Enhancement of antitumor activity of low-dose 5-fluorouracil by combination with Fuzheng-Yiliu granules in hepatoma 22 tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Body Weight; Cell Line, Tumor; Cell Proliferation; Drug S | 2013 |
Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent 5-Fluorouracil (5-FU).
Topics: Animals; Antineoplastic Agents; Body Weight; Female; Fluorouracil; Intestinal Mucosa; Mucositis; Pro | 2009 |
5-Fluorouracil induces diarrhea with changes in the expression of inflammatory cytokines and aquaporins in mouse intestines.
Topics: Animals; Antimetabolites, Antineoplastic; Aquaporins; Body Weight; Cytokines; Diarrhea; Etanercept; | 2013 |
Relationships between body composition parameters and fluorouracil pharmacokinetics.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Surface Area; Body | 2002 |
[Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer].
Topics: Animals; Body Weight; Cell Division; Colonic Neoplasms; Cyclohexanes; Disease Models, Animal; Drug C | 2002 |
Protective effects of glutathione on 5-fluorouracil-induced myelosuppression in mice.
Topics: Administration, Oral; Animals; Body Weight; Bone Marrow; Drug Antagonism; Female; Fluorouracil; Glut | 2003 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria.
Topics: Animals; Antimetabolites, Antineoplastic; Bacteria, Anaerobic; Bacterial Translocation; Body Weight; | 2003 |
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2003 |
[Effect and mechanism of orally administered leucovorin/5-fluorouracil on colon cancer].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colonic | 2003 |
Growth hormone protects the intestines but not the tumour from 5-fluorouracil toxicity in the short term in the rat.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Bacterial Translocation; Body W | 2004 |
A comparative pharmacology study between the intracolonic and oral routes of 5-FU administration in a colon cancer-bearing Yoshida sarcoma rat model.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Cell Count; Body Weight; Cathe | 2004 |
Alanyl-glutamine hastens morphologic recovery from 5-fluorouracil-induced mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Body Weight; Cell Division; Dipeptides; Dose-Re | 2004 |
Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Body Weight; Bromodeoxyuridine; Cell Proliferat | 2005 |
5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Body Weight | 2005 |
Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplasti | 2005 |
Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Cell Line, Tumor; C | 2005 |
Fluorouracil plus leucovorin induces submandibular salivary gland enlargement in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Bone Marrow Cells; Dose-Response Relationship | 2005 |
Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Camptothecin; Cell | 2005 |
Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Drug Combinations; | 2005 |
Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs.
Topics: Administration, Oral; Amine Oxidase (Copper-Containing); Animals; Antimetabolites, Antineoplastic; A | 2006 |
Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
Evaluation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters.
Topics: Administration, Topical; Alginates; Analysis of Variance; Animals; Anti-Inflammatory Agents; Anti-Ul | 2006 |
IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biolog | 2007 |
Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis | 2007 |
Intestinal toxicity induced by 5-fluorouracil in pigs: a new preclinical model.
Topics: Animals; Body Weight; Cell Shape; Drug Evaluation, Preclinical; Fluorouracil; Glutathione; Intestina | 2007 |
A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Body | 2007 |
Hemangiopoietin supports animal survival and accelerates hematopoietic recovery of chemotherapy-suppressed mice.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Body Weight; Bone Marrow Cells; Cell Movement; Cell | 2007 |
The effect of actinomycin D on mitosis in regenerating mouse liver.
Topics: Animals; Body Weight; Carbon Tetrachloride; Cell Division; Dactinomycin; Fluorouracil; Liver Regener | 1967 |
Studies of 6-N-hydroxylamino-9-beta-D-ribofuranosylpurine in mouse leukemia.
Topics: Adenine; Animals; Body Weight; Cytarabine; Drug Antagonism; Drug Synergism; Fluorouracil; Guanine; L | 1967 |
External carotid artery infusion with single-and multiple-drug regimens in the rat.
Topics: Animals; Antineoplastic Agents; Bleomycin; Body Weight; Carcinoma, Squamous Cell; Carotid Artery, Ex | 1980 |
Preliminary report on the effects of a four drug cytoxic protocol on wound healing in the rat.
Topics: Abdomen; Animals; Bleomycin; Body Weight; Drug Administration Schedule; Female; Fluorouracil; Inject | 1981 |
Modulation of 5-fluorouracil metabolism by thymidine. In vivo and in vitro studies on RNA-directed effects in rat liver and hepatoma.
Topics: Animals; Body Weight; Bone Marrow; Cell Survival; Fluorouracil; Intestinal Mucosa; Liver; Liver Neop | 1984 |
[Maximum tolerated dose of tegafur in rats].
Topics: Administration, Oral; Animals; Body Weight; Drug Administration Schedule; Drug Tolerance; Fluorourac | 1984 |
Anti-tumor effect of new 5-fluorouracil derivatives and their influences on the immune response.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Fluorouracil; Immunity; Injection | 1983 |
Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice.
Topics: Animals; Body Weight; Enbucrilate; Female; Fluorouracil; Leukopenia; Mice; Pharmaceutical Vehicles; | 1983 |
[Effect of FT-207 on bladder cancer in rats induced by BBN. II: The effect of oral administration of FT-207 during oncogenesis of bladder cancer].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Butylhydroxybutylnitrosamine; Flu | 1982 |
Microsomal metabolism of antipyrine in rats treated with antineoplastic drugs.
Topics: Animals; Antineoplastic Agents; Antipyrine; Body Weight; Cyclophosphamide; Fluorouracil; Kinetics; M | 1983 |
Adjuvant chemotherapy (CMF) for breast carcinoma: hematological side effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Carcinoma; Cyclophosp | 1982 |
5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling.
Topics: Animals; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Leukemi | 1981 |
Hypogonadism in male patients with metastatic cancer prior to chemotherapy.
Topics: Body Weight; Fluorouracil; Follow-Up Studies; Humans; Hypogonadism; Luteinizing Hormone; Male; Middl | 1982 |
Circadian rhythm and 5-fluorouracil toxicity in C3H mice.
Topics: Animals; Body Weight; Circadian Rhythm; Female; Fluorouracil; Mice; Mice, Inbred C3H; Mortality | 1982 |
[Effects of immunosuppressive drugs on the fetal-placental unit].
Topics: Animals; Body Weight; Female; Fetal Death; Fetal Resorption; Fluorouracil; Immunosuppressive Agents; | 1980 |
The differential effects of two salts of 5-fluorouracil and of dietary restriction on absorption by rat small intestine.
Topics: Animals; Body Weight; DNA; Fasting; Female; Fluorouracil; Intestinal Absorption; Male; Rats; Salts; | 1981 |
An experimental model for treatment of mesothelioma.
Topics: Animals; Asbestos; Body Weight; Cricetinae; Cyclophosphamide; Disease Models, Animal; Doxorubicin; F | 1981 |
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin.
Topics: Animals; Body Weight; Doxorubicin; Drug Therapy, Combination; Fibrosarcoma; Fluorouracil; Leukocyte | 1980 |
Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; C | 1994 |
Characteristics of peripheral blood monocytes and bone marrow macrophages from rats treated with mitomycin C, 5-fluorouracil or phenylhydrazine.
Topics: Animals; Blood Cell Count; Body Weight; Bone Marrow; Bone Marrow Cells; Cell Movement; Fluorouracil; | 1995 |
Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Division; Female; Fluorod | 1995 |
[Circadian chronotherapy for Walker-256 of Wistar rat].
Topics: Animals; Body Weight; Carcinoma 256, Walker; Circadian Rhythm; Combined Modality Therapy; Fluorourac | 1994 |
Circadian variation of 5-fluorouracil and cis-platinum toxicity in mice.
Topics: Animals; Body Weight; Bone Marrow; Bone Marrow Cells; Circadian Rhythm; Cisplatin; Drug Administrati | 1993 |
[Effect of BOF-A2 on experimental and spontaneous metastasis model of mouse colon 26].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Chemotherapy, Adjuvant; Colonic Neoplas | 1994 |
The roles of nutritional depletion and drug concentration in 5-fluorouracil-induced inhibition of colonic healing.
Topics: Anastomosis, Surgical; Animal Nutritional Physiological Phenomena; Animals; Body Water; Body Weight; | 1994 |
Suppression of mammary tumors by oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil in SHN virgin mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Female; Fluorouracil; Mammary | 1993 |
Polyamine increase in rat tissues treated with 1-beta-D-arabinosylcytosine and 5-fluorouracil.
Topics: Animals; Body Weight; Chromatography, High Pressure Liquid; Cytarabine; Fluorouracil; Male; Neoplasm | 1993 |
[Antitumor activity of combination treatment of BOF-A2 with CDDP against human lung cancers xenografted in nude mice].
Topics: Adenocarcinoma, Papillary; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Car | 1993 |
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1993 |
Tauromustine is more effective than conventional chemotherapy in the treatment of colonic tumors.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1993 |
[Effect of medroxyprogesterone acetate on antitumor efficacies and side effect of 5-fluorouracil].
Topics: Animals; Body Weight; Bone Marrow; Drug Synergism; Female; Fluorouracil; Lethal Dose 50; Male; Mamma | 1993 |
Diallyl disulfide suppresses the growth of human colon tumor cell xenografts in athymic nude mice.
Topics: Administration, Oral; Allyl Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemo | 1996 |
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Body Weight; Colorectal Neoplasms; Deoxygluc | 1996 |
The effects of 5-fluorouracil and interferon-alpha on early healing of experimental intestinal anastomoses.
Topics: Anastomosis, Surgical; Animals; Body Weight; Collagen; Drug Therapy, Combination; Fluorouracil; Hydr | 1996 |
New formulation of 5-fluorouracil in microspheres reduces toxicity in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Chemistry, Pharmaceutical; Drug Screening Ass | 1996 |
Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Squamous Cell; Combined Modality Therapy; Dr | 1996 |
[Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
Topics: Animals; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
Combined preoperative irradiation and direct postoperative 5-fluorouracil without negative effects on early anastomotic healing in the rat colon.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colorectal Neop | 1996 |
Fourteen-day oral combination dose toxicity study of CGS 16949 A (aromatase inhibitor) with 5-fluorouracil or tamoxifen in rats.
Topics: Administration, Oral; Animals; Aromatase Inhibitors; Blood Cell Count; Blood Chemical Analysis; Body | 1997 |
Sex- or age-related differences were not detected in the activity of dihydropyrimidine dehydrogenase from rat liver.
Topics: Aging; Animals; Body Weight; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Liver; Male; | 1997 |
The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Body Weight; Carbohydrate Sequence; Cell Differ | 1997 |
Regulation of the PepT1 peptide transporter in the rat small intestine in response to 5-fluorouracil-induced injury.
Topics: Animals; Body Weight; Carrier Proteins; Fluorouracil; Glucose; Glycine; Immunoblotting; Immunohistoc | 1998 |
Effects of levofolinate calcium on subacute intravenous toxicity of 5-fluorouracil in rats.
Topics: Animals; Antidotes; Antimetabolites, Antineoplastic; Body Weight; Bone Marrow; Drug Synergism; Eatin | 1998 |
Effect of trace element combination on the immune response of rats treated with cytostatic drug.
Topics: Adjuvants, Immunologic; Animals; Antibody-Producing Cells; Body Weight; Drug Combinations; Erythrocy | 1998 |
5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
Topics: Animals; Body Weight; Colorectal Neoplasms; Female; Fluorouracil; Leucovorin; Metabolic Clearance Ra | 1995 |
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoates; Body Weight | 1998 |
Longevity, stress response, and cancer in aging telomerase-deficient mice.
Topics: Aging; Alopecia; Animals; Body Weight; Bone Marrow Diseases; Fluorouracil; Hair Color; Longevity; Mi | 1999 |
Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Bile Ducts; Blotting, Northern; Body Weight; Cytochrome P- | 1999 |
Changes in intestinal absorption of 5-fluorouracil-treated rats.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Body Weight; Dextrans; Epithelial Cells; | 1999 |
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 1999 |
Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biotransformation; Body Weight; Chromatogr | 1999 |
Effect of dietary fiber on intestinal barrier function of 5-Fu stressed rats.
Topics: Animals; Bacteria; Body Weight; Colon; Dietary Fiber; Fluorouracil; Intestine, Small; Male; Permeabi | 1999 |
Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weigh | 1999 |
Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Bromodeoxyuridine; Enteritis; Fluorouracil; G | 2000 |
Enhanced efficacy of radioimmunotherapy combined with systemic chemotherapy and local hyperthermia in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality The | 2000 |
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Diarrhea; Digestive System; Drug Combi | 2000 |
Antitumor activity of 2-amino-4,4alpha-dihydro-4alpha, 7-dimethyl-3H-phenoxazine-3-one against Meth A tumor transplanted into BALB/c mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma; Female; Fluorouracil; Leukocyte Count; Mice; | 2000 |
Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Eating; Fluorourac | 2001 |
Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 16). Effects of short-term administration of carmofur on spermatogenesis.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Epididymis; Fluorouracil; Longevi | 2000 |
Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 18). Comparative 4 and 2 weeks oral repeated dosing studies on male reproductive organs in rats treated with 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Dose-Response Relationship, Drug; Eating; Epi | 2000 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; | 2001 |
Does the administration route of leucovorin have any influence on the impairment of colonic healing caused by intraperitoneal 5-fluorouracil treatment?
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Blood; Body Weight; Colon; Fluorour | 2001 |
Healing of experimental colonic anastomoses: effects of combined preoperative high-dose radiotherapy and intraperitoneal 5-fluorouracil.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colonic Disease | 2001 |
Comparative study between daily and 5-days-a-week administration of oral 5-fluorouracil chemotherapy in mice: determining the superior regimen.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Drug Administration Schedule; Fluorouracil; M | 2001 |
Influence of L-methionine-deprived total parenteral nutrition with 5-fluorouracil on gastric cancer and host metabolism.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; DNA, Neoplasm; Fluorouracil; Male; Methionine | 2001 |
Effects on fetal thymocyte populations and postnatal T-cell-dependent immune functions after maternal exposure to 5-fluorouracil during pregnancy in mice.
Topics: Animals; Animals, Newborn; Body Weight; Female; Flow Cytometry; Fluorouracil; Immune System; Immunos | 2002 |
[Parenteral feeding during aggressive chemotherapy of various neoplasms].
Topics: Adult; Bleomycin; Body Weight; Cachexia; Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Middl | 1978 |
The effects of 5-fluorouracil and 5-fluorodeoxyuridine used alone and in combination with normal nucleic acid precursors on development of mice in lines selected for low and high expression of Strong's luxoid gene.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Cell Survival; Drug Synergism; Female; Fetal Deat | 1975 |
Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine.
Topics: Animals; Body Weight; Digestive System; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; | 1979 |
Bronchorrhoea in a case of alveolar cell carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Atropine; Blood Sedimentation; Body Weight; Bronchoscopy; Cough | 1975 |
In vivo effects of 5-fluorouracil and ftorafur[1-(tetrahydrofuran-2-yl)-5-fluorouracil] on murine mammary tumors and small intestine.
Topics: Animals; Body Weight; Cell Division; DNA; Female; Fluorouracil; Intestine, Small; Male; Mammary Neop | 1979 |
Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Body Weight; Breast Neoplasms; Central Nervous Syst | 1979 |
A biochemical and pharmacological study of therapeutic synergism with 5-fluorouracil plus cyclophosphamide in murine L1210 leukemia.
Topics: Animals; Body Weight; Bone Marrow; Cyclophosphamide; DNA, Neoplasm; Drug Synergism; Drug Therapy, Co | 1979 |
Technique for in vivo perfusion of chemotherapeutic agents into the rat liver.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Body Weight; Chemo | 1979 |
Effects of 5-fluorouracil on the thiamin status of adult female rats.
Topics: Animals; Body Weight; Female; Fluorouracil; Liver; Organ Size; Rats; Spleen; Thiamine; Thiamine Pyro | 1979 |
Effect of 5-fluorouracil on liver and plasma vitamin A in female rats [proceedings].
Topics: Animals; Body Weight; Female; Fluorouracil; Liver; Organ Size; Rats; Vitamin A | 1979 |
Effects of 'elemental' diets on absorptive and enzymic activities and on 5-fluorouracil toxicity in rat small intestine.
Topics: Animals; Body Weight; Diet; Dipeptidases; Female; Fluorouracil; Glucose; Ileum; Intestinal Absorptio | 1979 |
The adverse effects of elemental diets on tolerance for 5-FU toxicity in the rat.
Topics: Amino Acids, Essential; Animals; Blood; Blood Proteins; Body Weight; Colon; Diarrhea; Diet; Dietary | 1977 |
Effect of 5-fluorouracil on liver regeneration and metabolism after partial hepatectomy in the rat.
Topics: Animals; Body Weight; Female; Fluorouracil; Hepatectomy; Lipids; Liver; Liver Neoplasms; Liver Regen | 1978 |
Antitumor agents. II. Effect of 5-fluorouracil and cyclophosphamide on immunological parameters and liver microsomes of tumor-bearing rats.
Topics: Alkaline Phosphatase; Animals; Body Weight; Cyclophosphamide; Fluorouracil; Immunosuppressive Agents | 1978 |
The role of diet on 5-fluorouracil toxicity.
Topics: Animals; Body Weight; Diet; Dietary Fats; Fatty Acids; Fluorouracil; Leukocyte Count; Male; Rats; Ti | 1978 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Body Weight; Cachexia; Evaluation Studies as Topic; Fe | 1975 |
Effects of nutrition on tumor growth and tolerance to chemotherapy.
Topics: Animals; Body Weight; Diet; Female; Fluorouracil; Glucose; Mammary Neoplasms, Experimental; Neoplasm | 1975 |
Antitumor agents. I. Effect of 5-fluorouracil and cyclophosphamide on liver microsomes and thymus of rat.
Topics: Alkaline Phosphatase; Animals; Body Weight; Cyclophosphamide; Cytochromes; Fluorouracil; Leukocyte C | 1976 |
Chemotherapy of a human malignant melanoma transplanted in the nude mouse.
Topics: Animals; Body Weight; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; F | 1975 |
Biological activity and molecular interaction of a netropsin-acridine hybrid ligand with chromatin and topoisomerase II.
Topics: Amsacrine; Animals; Body Weight; Cell Division; Chromatin; DNA Damage; Drug Design; Female; Fluorour | 1992 |
Influence of 5-fluorouracil and folinic acid on colonic healing: an experimental study in the rat.
Topics: Anastomosis, Surgical; Animals; Body Weight; Colon; Fluorouracil; Hydroxyproline; Leucovorin; Leukoc | 1992 |
Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Dose-Response Relationship, Dr | 1992 |
Antitumor activity of two novel low immunosuppressive fluoropyrimidines UK-21 and UK-25.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Fluorouracil; Glycine; Leukemia L | 1992 |
Intraperitoneal cytostatics impair healing of experimental intestinal anastomoses.
Topics: Anastomosis, Surgical; Animals; Bleomycin; Body Weight; Cisplatin; Colon; Fluorouracil; Hydroxyproli | 1991 |
Studies on the changes in plasma lipids and lipoproteins in CMF treated breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Cholesterol; Cisplati | 1991 |
Anti-tumor effect of L-methionine-deprived total parenteral nutrition with 5-fluorouracil administration on Yoshida sarcoma-bearing rats.
Topics: Animals; Body Weight; Cause of Death; Combined Modality Therapy; Disease Models, Animal; Evaluation | 1991 |
Effects of a three-drug antineoplastic protocol of wound healing in rats: a biomechanical and histologic study on gastrointestinal anastomoses and laparotomy wounds.
Topics: Anastomosis, Surgical; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Doxorub | 1991 |
Synthesis and antitumor activity of conjugates of 5-fluorouracil and chito-oligosaccharides involving a hexamethylene spacer group and carbamoyl bonds.
Topics: Animals; Antineoplastic Agents; Body Weight; Drug Carriers; Female; Fibrosarcoma; Fluorouracil; Inje | 1990 |
[Experimental studies on subrenal capsule assay using cyclosporin A treated mice--the optimal treatment schedules of CsA and anticancer agents (mitomycin C and 5-fluorouracil)].
Topics: Animals; Body Weight; Breast Neoplasms; Colonic Neoplasms; Cyclosporins; Female; Fluorouracil; Human | 1990 |
Indomethacin augments granulocyte-macrophage colony-stimulating factor-induced hematopoiesis following 5-FU treatment.
Topics: Animals; Body Weight; Colony-Stimulating Factors; Cyclophosphamide; Fluorouracil; Granulocyte-Macrop | 1990 |
Protein intake and 5-fluorouracil toxicity in tumor-bearing animals.
Topics: Animals; Body Weight; Diarrhea; Dietary Proteins; Female; Fluorouracil; Leukopenia; Mammary Neoplasm | 1990 |
Effects of L-2-oxothiazolidine-4-carboxylate, a cysteine pro-drug, on teratogenicity of 5-fluorouracil in mice.
Topics: Animals; Body Weight; Cystine; Drug Synergism; Female; Fluorouracil; Glutathione; Limb Deformities, | 1990 |
Healing of experimental colonic anastomoses: effect of antineoplastic agents.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Body Weight; Cisplatin; Colon; D | 1987 |
Combined therapy of polyamine antimetabolites and antitumor drugs for human gastric cancer xenotransplanted into nude mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcino | 1986 |
Biological activities of 5-fluorouracil and its prodrug 5'-deoxy-5-fluorouridine in rats.
Topics: Animals; Body Weight; Colonic Neoplasms; Drug Therapy; Female; Floxuridine; Fluorouracil; Prodrugs; | 1987 |
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Colorectal Neoplasms; Floxuridine; Fluor | 1988 |
[Antitumor effect of intermittent oral administration of UFT against human rectal cancer xenografted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Drug Adm | 1988 |
Effect of 1-hexylcarbamoyl-5-fluorouracil on development of rat urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Antineoplastic Agents; Body Weight; Butylhydroxybutylnitrosamine; Fluorouracil; Male; Nitro | 1988 |
The healing of colonic anastomoses after early intraperitoneal chemotherapy: an experimental study in rats.
Topics: Anastomosis, Surgical; Animals; Body Weight; Colon; Fluorouracil; Hemoglobins; Injections, Intraperi | 1988 |
Weight gain in women with localized breast cancer--a descriptive study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Combined Modal | 1988 |
[Effect and toxicity of entrapped polysiloxane 5-Fu polycondensate].
Topics: Animals; Body Weight; Bone Marrow; Cell Count; Delayed-Action Preparations; Female; Fluorouracil; Le | 1987 |
Experimental combination chemotherapy of ACNU and 5-FU against cultured glioma model (spheroid) and subcutaneous rat glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colony-Forming Units Assay; Di | 1987 |
[Biological radiation effects of carbon-14- and tritium-labeled 5-fluorouracil].
Topics: Animals; Body Weight; Carbon Radioisotopes; Fluorouracil; Injections, Intraperitoneal; Leukocyte Cou | 1987 |
Modulation of high-dose methotrexate toxicity by a non-toxic level of 5-fluorouracil.
Topics: Animals; Body Weight; Erythrocyte Count; Fluorouracil; Hematocrit; Hemoglobins; Leukocyte Count; Leu | 1986 |
Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Brea | 1986 |
Megestrol acetate therapy for advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; | 1985 |
Weight gain in patients receiving adjuvant chemotherapy for carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Combined | 1985 |
Decreased host toxicity in vivo during chronic treatment with 5-flourouracil.
Topics: Animals; Body Weight; Dihydrouracil Dehydrogenase (NAD+); Drug Administration Schedule; Drug Resista | 1985 |
A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy.
Topics: Adult; Aged; Body Weight; Combined Modality Therapy; Drug Administration Schedule; Female; Fluoroura | 1985 |
Weight gain during adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Body Weight; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Melphala | 1985 |
Induction by gonadal hormones of hepatic lipogenic enzyme activity in immature pullets.
Topics: Analysis of Variance; Animals; ATP Citrate (pro-S)-Lyase; Body Weight; Chickens; Cycloheximide; DNA; | 1974 |
Intravenous hyperalimentation in cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Body Weight; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Ne | 1974 |
Incorporation of thymidine after administration of fluorouracil and fluorouridine to adult and embryo mice.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Cleft Palate; Dose-Response Relationship, Drug; E | 1971 |
Enhancement of the antitumor activity of 5-fluorouracil by drug combinations.
Topics: Animals; Body Weight; Carcinoma, Ehrlich Tumor; Cell Count; Floxuridine; Fluorouracil; Hydroxyurea; | 1973 |
Primary cancer of the liver: a review of 25 cases and report of two prolonged survivals.
Topics: Adult; Aged; Body Weight; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatectomy; Humans; Live | 1972 |
[Combined action of serotonin, prednisolone and 5-fluorouracil on sarcoma 45 and M-1].
Topics: Administration, Oral; Animals; Body Weight; Drug Interactions; Drug Synergism; Fluorouracil; Injecti | 1974 |
Determination of endotoxicity in bacterial vaccines.
Topics: Acetone; Animals; Bacterial Vaccines; Body Weight; Cyclophosphamide; Dactinomycin; Drug Synergism; E | 1973 |
Antileukemic synergism between cyclophosphamide and an antitumor platinum compound.
Topics: Animals; Body Weight; Cisplatin; Cyclophosphamide; Drug Synergism; Drug Therapy, Combination; Fluoro | 1973 |
Proceedings: Rationale and results of primary endocrine therapy in patients with prostatic cancer.
Topics: Androgen Antagonists; Animals; Arginase; Body Weight; Castration; Cyclophosphamide; Cyproterone; Dis | 1973 |
Effects of 5-fluorouracil on drug-metabolizing enzymes in the rat.
Topics: Aniline Compounds; Animals; Body Weight; Cyclophosphamide; Depression, Chemical; Enzyme Activation; | 1974 |
Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors.
Topics: Amino Acids; Analgesics; Appetite; Body Weight; Breast Neoplasms; Carcinoid Tumor; Colonic Neoplasms | 1971 |
Elemental diet in the management of the intestinal lesion produced by 5-fluorouracil in the rat.
Topics: Alkaline Phosphatase; Amino Acids; Animals; Blood Cell Count; Body Weight; Depression, Chemical; Die | 1971 |
[Experimental studies on antineoplastic action of N 1 -(2'-tetrahydrofuryl)-5-fluorouracil (FT-207)--effect on experimental tumors].
Topics: Animals; Body Weight; Carcinoma, Ehrlich Tumor; Fluorouracil; Furans; Mice; Neoplasms, Experimental; | 1971 |
[Studies on the radio-cystostatic combination therapy. 5. Syncytostatic studies on 5-fluorouracil, Natulan and Proresid].
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Drug Synergism; Fluorouracil; Hydralazin | 1969 |
[Studies on the treatment of experimental renal tumors induced by dimethylnitrosamine. II. The effects of cancer chemotherapeutic drugs, such as mitomycin C, 5-fluorouracil and endoxan on experimentally induced renal tumors].
Topics: Animals; Body Weight; Cyclophosphamide; Fluorouracil; Injections, Intraperitoneal; Kidney Neoplasms; | 1969 |